


































Cover design:  Patricia Haak-Steeneveld 
 
Lay-out:  Yvonne Souverein 
 




© Copyright 2009 Yvonne van Leeuwen 
No part of this book may be reproduced, stored in a retrievel system or transmitted 
in any form or by any means, without the written permission of the author or, when 
appropriate, of the publishers of publications. 
Towards Improvement 
of 







ter verkrijging van  
de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties  
te verdedigen  
 
op donderdag 2 april 2009  
klokke 15.00 uur 
door 
 
Yvonne van Leeuwen 
 
 




Promotor:  Prof. dr. F.R. Rosendaal 
 
Copromotor:  Dr. F.J.M. van der Meer 
 
Referent:  Prof. Dr. S.D. Fihn  
(University of Washington, Seattle, USA) 
 
Overige leden: Prof. Dr. A. Algra  
(Universiteit van Leiden, Universiteit van Utrecht) 
Prof. Dr. M.M. Levi  








The work described in this thesis was performed at the department of Clinical 
Epidemiology, Leiden University Medical Center, Leiden, the Netherlands. Part of 
this thesis was a collaboration with the Bianchi Bonomi Hemophilia and 
Thrombosis Center, University of Milan, Italy.  
 
Financial support by the Netherlands Heart Foundation and the J.E. Jurriaanse 
Foundation for the publication of this thesis is gratefully acknowledged. 
 
Additional support was kindly provided by the Federatie van Nederlandse 
Trombosediensten (FNT), Astra Zeneca, CSL Behring and Roche Diagnostics 
Nederland B.V.
Table of Contents                        Page 
 
Chapter 1  General Introduction     7 
 
Chapter 2 Improved Control of Oral Anticoagulant Dosing:            19 
A Randomized Controlled Trial Comparing Two  
Computer Algorithms.  
J Thromb Haemost 2007; 5: 1644-9 
 
Chapter 3 The Relationship between Maintenance Dosages             37 
of Three Vitamin K Antagonists: Acenocoumarol, 
Warfarin and Phenprocoumon 
Thromb Res 2008;123(2):225-30. 
 
Chapter 4 Effects of CYP2C9 and VKORC1 on INR Variation        53 
and Dose Requirements during the Initial Phase of 
Anticoagulant Therapy with Acenocoumarol 
 Pharmacogenomics 2008; 9(9):1237-50 
 
Chapter 5 Prediction of Haemorrhagic and Thrombotic Events        83 
in Patients with Mechanical Heart Valve Prostheses 
Treated with Oral Anticoagulants 
J Thromb Haemost 2008; 3: 451-6 
 
Chapter 6 Determinants of Unstable Anticoagulation in Oral         101 
 Anticoagulant Treatment 
 Submitted for publication 
 
Chapter 7 A Randomized Controlled Trial Comparing Two           117 
Different Coumarins: Warfarin versus  
Phenprocoumon – General Results 
 
Chapter 8  General discussion & Summary                       131 
 
Chapter 9  Samenvatting               141 
 
   Dankwoord               153 
  












Thrombosis, or the formation of a blood clot which hampers blood flow in a 
bloodvessel, is a very serious disease which can potentially be fatal. Thrombosis 
can occur in arteries (arterial thrombosis) as well as in veins (venous thrombosis). 
The most commonly known forms of arterial thrombosis are thrombosis of the 
coronary arteries and the carotid arteries, which may cause myocardial infarction or 
ischaemic stroke. Venous thrombosis most commonly presents as an isolated 
thrombus in vessels of the leg, as a pulmonary embolism (which may be a clot 
formed in the legs, which has embolised to the pulmonary vasculature), or as a 
combination of both. An arterial thrombus mainly consists of platelets, whereas in 
venous thrombosis fibrin is the main component. Treatment and prevention of 
arterial and venous thrombosis is aimed at inhibiting platelet function or inhibition 
of coagulation. Three classes of anti-platelet drugs are currently approved for 
clinical use; cylooxygenase inhibitors (aspirin), P2Y12 inhibitors (such as 
clopidogrel), and inhibitors of platelet aggregation (such as Reopro). The most 
commonly used anticoagulant drugs are heparin and heparin derivatives and 
vitamin K antagonists.  
 
Vitamin K was discovered in 1929 by the observation of bleeding syndromes 
among chickens that were fed a fat-free diet [1]. This postulated the existence of a 
nutritional factor that was essential for normal haemostasis and Dam et al named 
this factor vitamin K. From clinical observations on patients with liver cirrhosis 
and obstruction from bile ducts it became clear that there was a direct link between 
liver function, bile secretion, vitamin K and the synthesis of clotting factors [2].  
In the early 1920s a veterinarian in North Dakota, USA described a 
haemorrhagic diathesis in cattle that was caused by the ingestion of spoiled, sweet 
clover [3]. In 1929 it was demonstrated that this bleeding disorder was caused by a 
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deficiency of functional prothrombin [4]. It wasn’t until 1940 that chemists of the 
University of Wisconsin discovered that the anticoagulant substance in the moldy 
sweet clover was the coumarin derivative 4-hydroxycoumarin [5]. In 1948 the first 
anticoagulant, warfarin (named for the Wisconsin Alumni Research Foundation), 
was produced [6]. It was first registered for use as a rodent poison. In 1954 
warfarin was approved for medical use in humans. The exact mechanism of action 
remained unknown until it was demonstrated, in 1978, that warfarin inhibited 
vitamin K epoxide reductase and hence interfered with vitamin K metabolism [7]. 
 
Vitamin K is essential for the function of vitamin K dependent coagulation factors. 
These specific proteins involved in the coagulation cascade are modified after 
synthesis by a vitamin K dependent process. Specific amino acid residues in the so-
called gla-domain are modified from a glutamic acid to a γ-carboxy glutamic acid 
by a vitamin K dependent carboxylase. In this process the vitamin K is oxidised to 
vitamin K epoxide. The γ-carboxy glutamic acid residues have a double negative 
charge at physiological pH, which is in contrast to the single negative charge of the 
(non modified) glutamic acid. The introduction of extra negative charge in the gla-
domain of the vitamin K-dependent proteins is essential for their Ca2+-mediated 
interaction with negatively charged cell membranes. Coagulation reactions take 
place on cellular surfaces – typically an activated platelet or endothelial cell. If the 
gla-domain of a vitamin K-dependent coagulation factor is not modified, the 
protein loses its capacity to bind to negatively charged cellular structures and thus 
is no longer able to participate in coagulation reactions. 
 Vitamin K antagonists exhibit their effect by interfering with the vitamin K 
cycle. Because the body is not able to store vitamin K, it is recycled through the 
vitamin K cycle. When vitamin K is oxidised in the carboxylation process 
described above it is no longer biologically active, and needs to be reduced by 




vitamin K epoxide reductase (VKOR). Vitamin K antagonists have structural 
similarity to vitamin K, and therefore reduce availability of biologically active, 
reduced vitamin K.  
Vitamin K is a necessary factor to produce the vitamin K-dependent 
clotting factors II, VII, IX and X, and the anticoagulant proteins C and S. Although 
both pro- and anticoagulant proteins are no longer post-translationally modified to 
biological active proteins in the presence of warfarin, the net effect of warfarin is 
an anticoagulant state. However, when warfarin treatment is initiated, it takes time 
for already circulating active coagulation factors to be replaced by inactive ones. 
The half-life of vitamin K-dependent coagulation factors varies from 4-6 hours 
(FVII) to 42-72 hours for prothrombin, so it will take 4-6 days before levels of 
activated coagulation factors are reduced to such an extent that sufficient 
anticoagulation is achieved. In some cases, particularly patients with anticoagulant 
protein deficiencies, this may lead for a short period to a hypercoagulable state 
with a risk of thrombosis. In order to bridge the period between initiation of 
anticoagulant treatment and the moment of sufficient vitamin K antagonist-induced 
anticoagulation, sometimes patients receive heparin for the first few days after 
initiation of anticoagulation, as heparin inhibits the coagulation system instantly. 
 
Worldwide there are different types of vitamin K antagonists available. The 
vitamin K antagonists most frequently used are warfarin, acenocoumarol and 
phenprocoumon. Warfarin is the vitamin K antagonist of choice in the United 
States of America, the United Kingdom and many other countries around the 
world; acenocoumarol and phenprocoumon are frequently used in many European 
countries. These three vitamin K antagonists mainly differ in their half-life. 
Acenocoumarol has the shortest half-life of 11 hours, followed by warfarin with 
36-42 hours and the longest half-life is seen in phenprocoumon with approximately 
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140 hours [8-11]. The clearance of these vitamin K antagonists is also different. 
Acenocoumarol is for its elimination completely dependent on hydroxylation by 
cytochrome p450 (CYP). Warfarin is also dependent on reduction processes [12]. 
Phenprocoumon can, in addition to elimination as hydroxylated metabolites, be 
eliminated as parent compound and is thus less dependent on hydroxylation by 
CYP. 
 
While vitamin K antagonists decrease the risk of a thrombotic event by inhibiting 
coagulation, through the same mechanism they increase the risk of severe or even 
fatal haemorrhage. Prescription of vitamin K antagonists should therefore always 
be preceded by a careful evaluation whether the benefit will outweigh the bleeding 
risk. Vitamin K antagonists have a narrow therapeutic window, and frequent 
monitoring with adjustment of anticoagulant dosage is required to maintain patients 
within the therapeutic window. The response to vitamin K antagonists in a single 
patient is highly variable and unpredictable. The intensity of anticoagulation is 
assessed with a simple laboratory test. In this test, plasma is allowed to clot by 
addition of a reagent containing tissue factor (the physiological initiator of 
coagulation), phospholipids and calcium. The time to clot formation is a measure 
of the functionality of the so-called extrinsic pathway of coagulation, which 
consists of coagulation factors VII, X, V, II, and fibrinogen. This particular 
coagulation test is referred to as the prothrombin time (PT). Although the PT is 
sensitive for anticoagulation with vitamin K antagonists, the tests are poorly 
standardised between different laboratories. Use of different reagents and 
equipment results in substantially different PT values from a single blood sample. 
To overcome this standardisation problem, the INR or international normalised 
ratio has been developed.   
 




The INR is assessed according to the formula: 
 
   INR = (patient PT/ mean normal PT)isi 
 
In this formula ISI is the International Sensitivity Index, which is the calibration 
factor to correct for the type of thromboplastin and equipment used. 
The introduction of the INR system to reflect anticoagulation led to several 
studies to determine the optimal level of anticoagulation, i.e. the level at which 
least complications occur [13-16]. The general recommendation is an INR between 
2.0 and 3.0. Sometimes, dependent on the indication, a more intense 
anticoagulation is needed for which the recommendation is an INR between 3.0 
and 4.0. In the Netherlands, the Dutch Federation of Anticoagulation Clinics 
(Federatie Nederlandse Trombosediensten, FNT) proposes target ranges of 2.5 – 
3.5 and 3.0 – 4.0.  
 
Patients who are insufficiently anticoagulated (i.e., an INR below the therapeutic 
window appropriate for their indication) are at increased risk for (re)thrombosis, 
whereas over-anticoagulated patients show a sharp increase in bleeding risk [16]. 
In spite of frequent monitoring, the annual risk for experiencing a serious bleeding 
complication is 1-2%[17,18]. Several studies investigated potential risk factors for 
haemorrhagic complications, such as increased age, indication for anticoagulant 
therapy and the use of interacting medication [19-21]. Besides these acquired 
factors, also genetic factors are shown to be of influence. Several studies have 
investigated the association between CYP2C9 genotype and warfarin response. 
Aithal et al. were the first to demonstrate an association between CYP2C9 
genotype and warfarin sensitivity. Carriers of a CYP2C9*2 or CYP2C9*3 allele 
have lower dosage requirement and showed an increased risk for over-
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anticoagulation and major bleeding complications in the initial phase of treatment 
compared to wild-type patients [22]. The presence of polymorphisms in the 
VKORC1 gene has also been identified to be associated with warfarin response. 
Carriers of VKORC1 polymorphisms showed a reduced requirement of warfarin 
dosage [23]. Most studies that investigate the effect of both the genotypes of 
CYP2C9 and VKORC1 showed that most variation in dosage is explained by 
polymorphisms in the VKORC1 gene. 
  
Although the quality of oral anticoagulant treatment is already high, improvement 
is important. The risk for complications rises sharply with INR values below 2.0 
and exponentially with INR values above 5.0 [16]. As a result of the large inter- 
and intra-patient variability in response to a certain dosage, patients may frequently 
be under- or overanticoagulated, despite frequent monitoring and adjustment of 
anticoagulant dose. Approximately 30 to 50% of the time, patients’ INR is out of 
range. Improvement can be targeted at several points. First, dosing of vitamin K 
antagonists can be improved. If physicians are able to predict a patients’ required 
maintenance dosage better, this would result in spending more time within the 
therapeutic range, and therefore in less complications. Dosing is classically 
performed by monitoring sequential INR values and the effect of previous dosing 
adjustments on the INR. Computer algorithms have been introduced to facilitate 
dosing and to produce a dosing advice based on mathematical processing of 
previous INR values and anticoagulant dosages. The use of these computer 
algorithms to assist physicians with their dosing decisions has been shown to lead 
to equal or improved quality of control of oral anticoagulant treatment compared to 
unassisted dosing [24-28]. However, a major disadvantage of these algorithms is 
that they do not generate a dosage proposal in all cases and they do not account for 




the sensitivity of the individual patient for the anticoagulant (which may change 
over time), the half-life of the drug, and the non-linearity of the dose-INR relation. 
Second, it is important to identify those patients who are at increased risk 
for experiencing either a thrombotic or a bleeding complication. Both patients who 
are unstably anticoagulated (large differences in sequential INRs) and patients who 
spend much time outside the therapeutic range are at risk. These patients can be 
more easily recognised when there is a measure to reflect their instability and if 
risk factors, either environmental or genetic, are identified. If one can recognise 
these patients actions such as patient education and more frequent monitoring can 
be taken. 
 
Outline of this thesis 
The studies included in this thesis aim to optimise dosing of vitamin K antagonists 
and control of oral anticoagulant treatment. 
In chapter 2 we describe the results of a double-blind randomised 
controlled trial in which we compared two computer algorithms for anticoagulant 
dosing. A newly developed algorithm which incorporated the sensitivity for 
vitamin K antagonists (ICAD) was compared to an algorithm frequently used in the 
Netherlands (TRODIS). 
The relationships between maintenance dosages between the three most 
used vitamin K antagonists acenocoumarol, warfarin and phenprocoumon were 
studied in chapter 3. We calculated transition factors for switching from one 
vitamin K antagonist to another among participants in a randomised controlled trial 
who were treated with 2 different vitamin K antagonists. 
In chapter 4 the effects of polymorphisms in the CYP2C9 and VKOR 
genes were investigated in a cohort of patients starting with oral anticoagulant 
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treatment with acenocoumarol in Italy. We described the effect of these 
polymorphisms on the dose requirement and the risk of over-anticoagulation. 
Instability is considered a risk factor for developing hemorrhagic and 
thrombotic complications. In chapter 5 we studied several methods to reflect 
instability and investigated which method was best associated with hemorrhagic 
and thrombotic events in patients with mechanical heart valve prosthesis treated 
with vitamin K antagonists. Determinants of instability were investigated in 
chapter 6. 
Finally, in chapter 7 we present the study design and general results of a trial of 
which the primary aim was to compare the quality of an oral anticoagulant 
treatment with warfarin to the quality of treatment with phenprocoumon. 
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Background Efforts to improve dosing quality in oral anticoagulant control include 
the use of computer algorithms. Since current algorithms are simplistic and give 
dosage proposals in a small fraction of patients, we developed an algorithm based 
on principles of system and control engineering that gives proposals in nearly all 
patients.  
Objective We evaluated the new algorithm in clinical practice. 
Patients and Methods We conducted a double-blind randomized controlled trial 
among 712 patients with an indication for long-term anticoagulant treatment at the 
Leiden Anticoagulation Clinic. We compared oral anticoagulant dosing supported 
by the new algorithm (ICAD) with the standard algorithm (TRODIS).  
Results The percentage of time spent in therapeutic range was similar for the new 
and standard algorithm group, 79.8% versus 80.2% (Diff 0.4%, 95%CI –1.7% to 
2.6%). The new algorithm produced a dosage proposal in 97.5% of visits and the 
standard algorithm in 60.8% (Diff 36.7%, 95%CI 35.4%-38.0%).  79.3 % of 
proposals of the new algorithm were accepted by the physician versus 90.9% for 
the standard algorithm (Diff 11.6%, 95%CI 10.2%-13.0%). This implies that the 
new algorithm gave an acceptable proposal in 77.4% of all patient visits versus 
55.3% for the standard algorithm (Diff 22.1%, 95%CI 20.4%-23.8%). 
Conclusions Substantially more dosage proposals were generated and accepted 
with the new than with the standard algorithm, and the new algorithm will 
therefore improve the efficiency of anticoagulant monitoring without loss of 
quality. 
 





Management of oral anticoagulant treatment is difficult due to the large variability 
in the dosage needed to achieve the optimal anticoagulant effect. Sensitivity for 
vitamin K antagonists not only differs between patients, but also within patients it 
may vary over time [1]. 
The use of computer algorithms to assist physicians with their dosing 
decisions has been shown to lead to equal or improved quality of control of oral 
anticoagulant treatment compared to unassisted dosing [2-6]. Several algorithms 
have been developed previously. Poller et al. compared three different 
computerized systems to assist warfarin control to traditional dosing by 
experienced doctors. They found roughly similar results for unassisted dosing by 
physicians and dosing by the three algorithms [7]. In a larger multicenter study 
Poller et al. evaluated the safety and efficacy of the DAWN AC anticoagulant 
therapy management system. They found that patients in the computer-dose group 
spent more time in the target range than patients in the traditional-dose group [8]. 
An algorithm that is similar to these algorithms is used widely in the Netherlands 
(TRODIS) [9]. This algorithm generates a dosage proposal in approximately 55% 
of visits, leaving 45% for unassisted dosing by experienced physicians. In 
approximately 20% of cases where TRODIS generates a dosage proposal, it is 
overruled by a physician [10]. All these algorithms are based on an empirical 
decision-tree that determines whether the same dosage can be maintained, dosage 
adjustments have to be made or manual intervention by a physician is required. The 
equations used by the algorithm are based on a simple pharmacodynamic model, 
which implies a linear function between the INR and the dosage. A major 
disadvantage of these algorithms is that they do not generate a dosage proposal in 
all cases and they do not take into account the sensitivity of the patient for 
 




coumarin derivatives (which may change over time), the half-life of the drug, and 
the non-linearity of the dose-INR relation. 
 To improve computer assisted dosing, we developed a new dosing 
algorithm. The Improved Control of Anticoagulant Dosage (ICAD) algorithm is 
based on a model that comprises pharmacokinetics and pharmacodynamics of the 
oral anticoagulant drug, pharmacokinetics of the prothrombin complex and the 
relation between the activity of the prothrombin complex and the measured INR. It 
consists of two sub models in which the first sub model describes the collective 
influence of all processes on the effect of the vitamin K antagonist and the second 
sub model describes the relationship between the dosage and the corresponding 
INR. The second sub model includes a variable parameter to reflect the sensitivity 
of the patient that may change over time. In an expert evaluation 194 visits were 
randomly selected from the anticoagulation clinic database to assess whether the 
dosage proposal and appointment periods calculated by the algorithm were 
acceptable. In this evaluation the ICAD algorithm was able to give a good or 
acceptable proposal in 94.3%. The ICAD algorithm is described in detail elsewhere 
[11]. 
 In this study we tested the ICAD algorithm in clinical practice in a double-





The study was conducted at the Leiden Anticoagulation Clinic in the Netherlands. 
Patients visit the clinic to have their INR measured and they receive their daily 
dosage prescription the next day by mail [12]. The TRODIS program uses the 
previous two INRs, the previous dosage schedule, the INR target and range 
 




limiting values of the INR. A dose-response model is used to predict an INR. By 
comparing this prediction with the measured INR the program computes a new 
dosage and the time to the next visit. It does not generate a proposal in case of an 
alert (e.g. when a new drug is prescribed) or a large difference between the actual 
and the target INR and in that case the physician has to determine the dosage 
without any help of the algorithm. 
 The ICAD algorithm also uses the actual measured INR, the target INR 
and the previous dosage schedule, but differs from TRODIS and all other 
algorithms by calculating the sensitivity of the patient during the full course of 
each treatment. This sensitivity is incorporated in the equation to estimate the 
dosage needed to achieve optimal anticoagulant effect, thus allowing the dose-INR 
relationship to change over time. As all other algorithms ICAD gives a 
recommendation for the dosage as well as an appointment period. 
 A computer program was developed for this study to present dosage 
proposals of both algorithms in an identical way to keep physicians blinded. This 
program extracted for every patient the dosage proposal generated by TRODIS 
along with the INR, previous dosage schedule and all previous INRs from the 
TRODIS mainframe database. The relevant data were led through the ICAD 
algorithm, and an ICAD proposal was generated; so for all patients a TRODIS as 
well as an ICAD proposal was available. Dependent on the group the patient was 
randomized to, the TRODIS or the ICAD proposal was shown to the physician, on 
a screen that was identical for both types of proposals. Along with the dosage 
proposal a recommendation about the appointment period was given. Both ICAD 
and TRODIS give an indication on how confident the algorithm is about the 
proposal; for TRODIS, there are two levels of confidence (‘high’ and ‘tentative’), 
while ICAD expresses confidence in a range of 0-100. These levels of confidence 
were not shown to the physician to maintain blinding, but are used in the analyzes 
 




presented here. The physician could either accept or overrule the generated 
proposal. The final dosage was led back to the mainframe database of the 
anticoagulation clinic and subsequently, as is the routine policy, communicated by 
mail to the patient. 
We obtained approval from the Medical Ethics Review Committee of the 
Leiden University Medical Center before start of the study and each patient gave 
written informed consent. 
 
Patients 
Enrolment occurred between August 14th and October 16th 2003 at the Leiden 
Anticoagulation Clinic. Patients were eligible when they were already on 
anticoagulation with an indication for long-term anticoagulant therapy and were 
aged between 18 and 80. Patients were excluded when they were on patient self-
management, stayed long periods abroad or were in a terminal stage of disease. 
Randomization was stratified by the indication for oral anticoagulant treatment, age 
and sex using the minimization method [13]. The study was double blind, e.g., 
neither patients nor physicians were aware which group the patient belonged to. 
Follow-up was until September 1st 2004, i.e. maximally about one year. 
 
Analysis 
The analysis was performed at two levels, i.e., on the level of the patient and on the 
level of the proposal. In the first analysis, the primary outcome measure for this 
comparison was quality of anticoagulant treatment defined as the mean percentage 
of time spent in the therapeutic range (TTR) calculated with the linear interpolation 
method [14]. Therapeutic ranges were as they were applied in our routine 
anticoagulant practice: INR 2.0 to 3.5 for low intensity and INR 2.5 to 4.0 for 
indications requiring a higher intensity. In case a patient had 2 or less INR 
 




measurements in total, no TTR was calculated. When the time between two INR 
checks exceeded 9 weeks, no TTR was calculated for this period, and this period 
was excluded. All periods of hospitalization were excluded. 
 Secondary outcome measures were the median time between visits, the 
percentage of time above or below the therapeutic range, the number of dosage 
proposals generated by the algorithm and clinical events. Bleeding complications 
were classified as major if they were fatal or necessitated hospitalization. Minor 
bleeding complications were all other bleeding events, in which ecchymoses were 
only counted when more than 10 cm diameter and epistaxis only when the duration 
exceeded 30 minutes.  
In the analysis at the level of the proposal, we compared the proposals as 
they were generated by each algorithm (of which only one was shown to the 
physician). The primary outcome measure was the quality of the dosage proposals, 
expressed as the percentage accepted by the physician. In case no proposal was 
generated we considered this as not accepted. Secondary outcomes at the level of 
proposal comparisons were the percentage of INRs within the therapeutic range at 
the next visit, the percentage of accepted appointment periods proposed by the 
algorithms and whether the dose proposal of the algorithm which was not shown to 
the physician differed from the given dose. 
We knew beforehand that TRODIS is not always capable of generating a 
dosage proposal. If the algorithm was incapable of generating a proposal, the 
dosage had to be determined by the physician unassisted by the algorithm. ICAD 
generated a dosage proposal in nearly all visits, which made it possible to directly 
compare ICAD with the physician. To avoid bias we selected all INR checks from 
both randomization groups where TRODIS was not able to generate a proposal. 
This was possible because for all visits an ICAD as well as a TRODIS proposal 
was available. In patients randomized to TRODIS the physician determined the 
 




dosage without assistance of the algorithm. In the patients randomized to ICAD, an 
ICAD proposal was available. We studied the performance of the physician versus 
ICAD in these two groups by calculating the percentage of INRs within range at 
the next visit.  
 
Statistical Analysis 
We determined the necessary sample size on our primary outcome measure the 
time in therapeutic range. We felt a difference of 5% in percentage of time spent in 
therapeutic range to be of clinical relevance. Based on information of several 
anticoagulation clinics we found a standard deviation of approximately 23% in this 
outcome measure. With an alpha of 5% and a power of 90% we needed two times 
168 patients to detect our clinical relevant difference. To allow us to do subgroup 
analyzes we included 712 patients. 
All outcomes are shown as means or percentages with the corresponding 
95% confidence interval of the difference based on T or binomial distributions or 
medians with the corresponding interquartile range (IQR). All calculations were 
performed on intention-to-treat basis using the statistical package SPSS version 
14.0 (SPSS Inc, Chicago, Ill). 
The authors had full access to the data and take responsibility for its 
integrity. All authors have read and agree to the manuscript as written. 
 
Results 
Seven-hundred-and-twelve patients were randomized, 359 were assigned to ICAD 
and 353 to TRODIS. Total follow-up time in the ICAD group was 283.1 person-
years during which 6007 INR checks were performed. In the TRODIS group 
follow-up time was 278.7 person-years with 5920 INR checks. Enrolment, 
randomization, follow-up and analysis of all patients are summarized in figure 1. 
 






Figure 1. Enrolment, Randomization and Data Analysis  
 




Table 1. Patient characteristics 




Age   
 Mean (IQR) 65.7 (59.6-74.8) 64.6 (57.6-74.8) 
Sex   
 Men (%) 66.6  66.6  
Indication   
 Atrial Fibrillation (%) 44.5  42.3  
 Venous thrombosis (%) 11.6  13.3  
 Heart valve prosthesis (%) 9.9  10.6  
 Other cardiac indication (%) 20.1  16.7  
 Peripheral vascular disorder (%) 8.8  10.3  
 Cerebrovascular (%) 5.1  7.0  
Coumarin   
 Acenocoumarol (%) 13.6  12.5  
 Phenprocoumon (%) 85.6  86.1  
 Switched (%) 0.8  1.4  
Intensity (target)   
 Low (2.5 – 3.5) (%) 62.9  61.6  
 High (3.0 – 4.0) (%) 36.3  38.2  
 Switched (%) 0.8  0.3  
 
Baseline characteristics are shown in table 1. 
The mean TTR was 79.8% in the ICAD group and 80.2% in the TRODIS 
group (Diff 0.4%, 95%CI of diff –1.7% to 2.6%). The mean percentage of time 
spent at sub- or supratherapeutic INRs did not differ: 4.2% of time subtherapeutic 
in the ICAD group versus 4.4% in the TRODIS group (Diff 0.2% 95%CI of diff –
1.1% to 1.5%), 16.0% of time supratherapeutic in the ICAD group versus 15.4% in 
the TRODIS group (Diff 0.6%, 95%CI –1.1% to 2.3%). The median time between 
two visits in the ICAD group was 14 days (interquartile range (IQR) 14-26 days) 
versus 14 days (IQR 14-22 days) in the TRODIS group (Figure 2). 
There were 98 bleeding events (17 major and 81 minor) and 3 thrombo-
embolic complications in 85 patients. Overall incidence of clinical thrombo-
embolic and bleeding events (allowing for more than one event per patient) was 
19.4/ 100 py in the ICAD group vs. 16.5/ 100 py in the TRODIS group, yielding a 
relative risk of 1.2 (95%CI 0.8-1.8).  
 
 























































Figure 2. Time between two visits 
 
Twelve of the major bleeding events occurred in the ICAD group (incidence rate 
4.2/ 100 person-years), 5 in the TRODIS group (incidence rate 1.8/ 100 person-
years). This yielded a relative risk of 2.3 (95%CI 0.8-6.5) of excess bleeding in the 
ICAD vs. TRODIS group. In the ICAD group 5 major bleeding events were 
gastrointestinal, 2 haematuria, 1 severe nose bleed and 1 severe skin bleed. In the 
TRODIS group there were 2 severe nose bleeds, 1 respiratory tract bleed and 1 
retroperitoneal bleed. To further investigate the major bleeding events we analyzed 
in addition to the mean TTR, time spent with an INR <2.0, 2.0 - 3.0, 3.0 - 4.0, 4.0 – 
5.0 and above 5.0. Also in this analysis there was no difference between the ICAD 
group and the TRODIS group. Of six patients there was an INR measurement 
available within 7 days before the event, of which only one was above range (INR 
4.7, ICAD). Of the remaining patients who had their last INR measurement more 
than 7 days ago three had an INR that was marginally above range (2 ICAD, 1 
TRODIS) and two below range (1 ICAD, 1 TRODIS). In none of the patients the 
dosage was increased at the last INR measurement. In total 21 patients died during 
 




follow up, 4 because of a bleeding complication (3 ICAD, 1 TRODIS). All deaths 
and complications are listed in table 2. 
 
Table 2. Adverse events and deaths during follow up. 




Bleeding events   
 Minor 40 41 
 Major 4 9 
 Fatal 1 3 
 Total 45 53 
Thrombo-embolic events 1 2 
   
Deaths   
 Bleeds 1 3 
 Malignancy 1 2 
 Cardiac 2 0 
 Respiratory 0 3 
 Other 1 1 
 Unknown 4 3 
 Total 9 12 
 
 
ICAD was able to generate dosage proposals in 97.5 % of visits, whereas 
TRODIS generated a proposal in 60.8% (Diff 36.7%, 95%CI: 35.4% to 38.0%). In 
the ICAD group 79.3% of these dosage proposals was accepted versus 90.9% in 
the TRODIS group (Diff 11.6%, 95%CI: 10.2% to 13.0%). In total, therefore, 
77.4% of patient visits in the ICAD group led to an accepted proposal, which was 
55.3% in the TRODIS group (Diff 22.1%, 95%CI 20.4% to 23.8%). In ICAD 
software problems were the main reason for not generating a proposal, which 
occurred only rarely. The most important reason for rejecting a proposal was that 
the dosage change proposed by the algorithm was estimated to be too strong 
(66.2%). In TRODIS the main reason why a proposal was not generated was an 
INR change that was too large in relation to the previous INR or the one before that 
(64.2%). In case of a rejected proposal this was mostly because the dosage change 
proposed by the algorithm was too strong (66.2%) (Table 3). 
 









Reasons N (%) N (%) 
Dosage change proposed by the algorithm was too strong 733 (60.5) 217 (66.2) 
Dosage change proposed was not strong enough 339 (28.0) 60 (18.3) 
Proposal was in the wrong direction 139 (11.5) 51 (15.5) 
 
 
When the proposals were stratified according to the confidence level the 
algorithm had given to it, in both groups the proportion of proposals that was 
accepted rose with the confidence level (Table 4). Along with the dosage proposal 
the algorithms also provided a proposal for the appointment period. The proposed 
appointment periods were accepted in 76.5% in the ICAD proposals and 91.4% in 
the TRODIS proposals (Diff 14.9%, 95%CI of diff: 13.5%-16.3%). When we only 
considered proposals of which the physician accepted the dosage, 82.1% of the 
ICAD appointment periods were accepted and 93.4% in the TRODIS group (Diff 
11.3%, 95%CI of diff: 9.9-12.7). 
 
Table 4. Percentage of accepted dosage proposals stratified according to the confidence levels. 
TRODIS    
  N (%) % Accepted 
TRODIS proposal type   
 No proposal 2319 (39.2) 0 
 Tentative 1465 (24.7) 87.6 
 Confident 2136 (36.1) 93.1 
Total  5920 55.3 
    
ICAD    
  N (%) % Accepted 
ICAD confidence score   
 0-20 228 (3.8) 7.9 
 20-40 367 (6.3) 37.3 
 40-60 939 (15.6) 64.9 
 60-80 2001 (33.3) 80.1 
 80-100 2472 (41.2) 92.4 
Total  6007 77.4 
 
 





In the ICAD group 70.1% of INRs were in range at the next visit, 
compared to 72.5% of INRs in the TRODIS group (Diff. 2.4%, 95%CI of diff.: 
0.7% to 4.1%). When we only consider the accepted proposals, 72.3% of the INRs 
was in range in the ICAD group, versus 75.7% in the TRODIS group (Diff 3.4%, 
95%CI of diff 1.4-5.4). Of the TRODIS proposals that were overruled by the 
physician, 28.0% had an ICAD proposal which was equal to the dosage that was 
given by the physician. In the ICAD group, 19.1% of the unaccepted proposals had 
a TRODIS proposal that was similar to the actual given dosage. 
In the comparison between ICAD and the physician, i.e., all patient visits 
where TRODIS was not capable of giving a proposal, ICAD was able to generate a 
dosage proposal in 96.9% of cases. Of these, 66.7% was accepted by the physician. 
In the ICAD group 63.4% of the INRs were within the therapeutic range at the next 
INR measurement versus 67.4% in the TRODIS group, which were dosed by the 
physician (Diff 4.0%; 95%CI of diff 1.2–6.8). 
 
Discussion 
In this study we compared two computer algorithms for control of anticoagulant 
dosing. There was no difference in quality of anticoagulant control between the 
TRODIS and the ICAD algorithm, expressed as mean time in therapeutic range. 
Also, the time between two visits was similar in both groups, although the 
interquartile range was broader for the new algorithm. There was a difference in 
efficiency between the two algorithms. For all visits, TRODIS generated an 
acceptable proposal in 55.3%, which was 77.4% for ICAD. Finally, in almost all 
cases where the standard algorithm could not give a proposal, the new algorithm 
could, and performed equally well as an unassisted physician. 
 




The similar quality of ICAD and TRODIS proposals can be explained in 
several ways. First, it is possible that an algorithm which uses more information of 
a patient is not capable of generating dosage proposals better than an algorithm 
which uses less information. Second, it is possible that there can be no more gain in 
quality of treatment by improving dosing of anticoagulants. Thirdly, physicians 
being used to the old algorithm, may have altered unusual but good proposals of 
the new algorithm. We feel that it is unlikely that an algorithm will ever be capable 
of incorporating all aspects of patient behavior, such as sudden changes in diet, and 
that possibly the best that is attainable is an algorithm that does as well as well-
trained, dedicated physicians. When one algorithm uses a simple model and only 
gives proposals for ‘easy’ cases, leaving the more difficult cases to the physicians, 
while another algorithm gives proposals for virtually all cases and performs as well 
as the physicians, the result would be as we observed: an increase in efficiency 
without a concomitant increase in quality of treatment. 
Although there was no difference in mean time in therapeutic range 
between the groups, we did observe a difference in clinical events. Since the study 
groups were similar in all prognostic variables and the time in therapeutic range 
was similar for both groups we feel this was due to chance. Also, in the additional 
analysis we found again no difference between the two groups and most bleeding 
events were at INR in range, which strengthens our idea that the difference was due 
to chance. 
This study was double blind, so patients in both groups were treated the 
same way except for the algorithm that was used. Bias resulting from a different 
attitude towards the two algorithms was therefore prevented. In some cases 
blinding of the physicians could not be achieved. It was known beforehand that 
TRODIS often is not able to generate a proposal. Whenever there was no proposal 
available, the physician knew that in all likelihood this concerned a patient 
 




randomized to the TRODIS group. This was only known for the INR check at that 
time, for the physician did not see previous proposals. Since in these cases there 
was obviously no possibility to reject or accept the proposal, it is difficult to 
imagine that this could have biased the results. 
Some patients were lost to follow-up after randomization because of 
participation in a self management program, end of the prescribed treatment period 
or other reasons. In both groups the same number of patients was lost to follow-up, 
and their numbers were small, so that selection due to loss of patients is unlikely. 
We have tested the new ICAD algorithm for computer-assisted dosing of 
oral anticoagulants in a randomized blinded comparison to the algorithm that is 
currently in use. The ICAD algorithm led to similar quality of anticoagulant 
control, but proved to perform more efficiently: overall the proportion of proposals 
that were accepted was 77.4%, versus 55.3% for the old algorithm. Therefore, the 
newly developed ICAD algorithm is an important gain in the efficiency of the 
management of oral anticoagulant therapy. 
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Introduction Vitamin K antagonists of the coumarin type are widely used oral 
anticoagulants. 
Objective We developed a transition algorithm for the maintenance dosages of 
three frequently used coumarins: warfarin, phenprocoumon and acenocoumarol. 
Methods  The study was conducted at the Leiden Anticoagulation Clinic. Patients 
were participants in a trial of which the main objective was to compare the quality 
of an oral anticoagulant therapy with phenprocoumon to warfarin. We included 
patients who initiated oral anticoagulant therapy and patients who were already 
using acenocoumarol. Patients were randomized to a treatment with warfarin or 
phenprocoumon. Patients who were randomized to warfarin switched to 
phenprocoumon at end of follow up. We analysed the switch from acenocoumarol 
to warfarin or phenprocoumon at start of follow up and the switch of warfarin to 
phenprocoumon at the end of follow up and calculated the transition factors for 
stable anticoagulation between these three vitamin K antagonists. 
Results 58 patients switched from warfarin to phenprocoumon, 39 from 
acenocoumarol to phenprocoumon and 44 from acenocoumarol to warfarin. The 
maintenance dose of warfarin was 0.41 (95%CI 0.39- 0.43) times the maintenance 
dose of phenprocoumon. The transition factor between acenocoumarol and 
phenprocoumon was 0.84 (95%CI 0.79- 0.89) and between acenocoumarol and 
warfarin 1.85 (95%CI 1.78- 1.92).  
Conclusions We determined the transition factors between warfarin, 
phenprocoumon and acenocoumarol. With these transition factors physicians are 
able to estimate the maintenance dose when it is necessary for a patient to switch 
from one coumarin to the other. 





Vitamin K antagonists of the coumarin type are widely used oral anticoagulants. 
They are proven to be effective in the treatment and prevention of arterial and 
venous thrombosis [1-3]. Worldwide there are different coumarin derivatives 
available. The coumarins most frequently used are warfarin, acenocoumarol and 
phenprocoumon. Warfarin is the coumarin of first choice in the United States of 
America, the United Kingdom and many other countries around the world; 
acenocoumarol and phenprocoumon are frequently used in many European 
countries. These three coumarin derivatives mainly differ in their half-life. 
Acenocoumarol has the shortest half-life of 11 hours, followed by warfarin with 
36-42 hours and the longest half-life is seen in phenprocoumon with approximately 
140 hours [4-7]. Also the clearance of these coumarins is not similar. 
Acenocoumarol is for its elimination completely dependent on hydroxylation by 
cytochrome p450 (CYP). Warfarin is also dependent on reduction processes [8]. 
Phenprocoumon can, in addition to elimination as hydroxylated metabolites, be 
eliminated as parent compound and is thus less dependent on hydroxylation by 
CYP. These differences in dependence on hydroxylation by the CYP enzymes offer 
an explanation of different responses found in studies investigating the effects of 
polymorphisms in the CYP2C9 gene [9,10]. Several studies have compared the 
different coumarins with regard to the quality of treatment, e.g. stability. Most 
studies have compared the short acting acenocoumarol to the longer acting 
warfarin or phenprocoumon. The results were mostly in favour of the longer acting 
coumarins, but not always [11-19].  
Sometimes transition from one coumarin to another is required. Reasons to 
switch can be women trying to get pregnant for whom the use of phenprocoumon is 
contra-indicated because of its long half-life and acenocoumarol is preferred, the 
experience of allergic reactions or side effects such as hair loss. Coumarin 




sensitivity can be a reason to switch from one coumarin to the other for practical 
reasons, since a maintenance dose of less than 1 mg of acenocoumarol is difficult 
to administer (tablets contain 1 mg, and cannot be divided). Finally, patients who 
are very instable are sometimes thought to benefit from switching to another 
coumarin derivative with a longer half-life. At present, literature about the 
transition from one coumarin to another is surprisingly scarce. One study 
investigated a dosage scheme for transition from phenprocoumon to warfarin in 
patients treated in an outpatients clinic [20]. The authors found that the dosage for 
an optimal INR of warfarin is 2.3 times the dosage of phenprocoumon. Applying 
this transition factor resulted in 75% of patients for whom the right dosage could be 
determined. No studies are known that included transition to or from 
acenocoumarol. 
We studied the relationship between the maintenance dosages of 
acenocoumarol, warfarin and phenprocoumon in patients participating in a 
randomized controlled trial. 
 
Methods 
Study design and patient population 
Patients participated in a randomized controlled trial conducted at the Leiden 
Anticoagulation clinic. Inclusion of patients occurred between February 2004 and 
April 2007. The main objective of the trial was to compare the quality of oral 
anticoagulant treatment with phenprocoumon versus warfarin. Follow-up was six 
months. Patients were eligible to participate when they were aged between 18 and 
85 years and had an indication for anticoagulant treatment for at least three months. 
Exclusion criteria were pregnancy or intended pregnancy, renal dialysis, 
chemotherapy, known allergic reactions for warfarin or phenprocoumon or a 
contra-indication to oral anticoagulant treatment. 




Two patient groups were included in the trial. The first group consisted of 
patients initiating oral anticoagulant treatment and was recruited in three hospitals, 
i.e., at the departments of Cardiology and Internal Medicine of the Leiden 
University Medical Center, Diaconessenhuis Leiden and  Rijnland Hospital 
Leiderdorp and at the department of Orthopedics of the Leiden University Medical 
Center, all in the Netherlands. Patients were randomized to a treatment with either 
phenprocoumon or warfarin and were followed until end of treatment or, when the 
indication required the treatment to continue over 6 months, follow-up ended at 
this point. Because warfarin is not registered for use in the Netherlands patients 
who required ongoing treatment and who were randomized to the warfarin group 
were switched to a treatment with phenprocoumon. 
The second group included in this trial consisted of patients already using 
acenocoumarol and were recruited at the Leiden Anticoagulation clinic. After 
written informed consent they were randomized and switched to a treatment with 
either phenprocoumon or warfarin. Follow-up was again 6 months and like patients 
of the first group, patients randomized to warfarin switched to phenprocoumon at 
the conclusion of the trial. If they preferred so, patients of this second group could 
also choose to switch back to acenocoumarol. Figure 1 summarizes the flow of 
patients through the study.  
All patients participating in the trial were part of the routine care in the 
Anticoagulation clinic. We obtained approval from Medical Ethics Review 
Committee of the Leiden University Medical Center before start of the study and 
all patients gave written informed consent before randomization. The trial is 












Figure 1.  Flowchart of patients in the trial  
 
Analysis 
Of the first group of patients, i.e., those who initiated their treatment within the 
trial, we studied the transition of patients randomized to warfarin who switched to 
phenprocoumon at end of follow-up. Of the second group of patients, i.e., those 
already treated with acenocoumarol, we studied the transition from acenocoumarol 
to phenprocoumon or warfarin at start of follow-up and the transition from warfarin 
to phenprocoumon at end of follow-up. We did not include the transition from 
warfarin to acenocoumarol at the end of follow-up because these patients were 




already included in the analysis as switchers from acenocoumarol to warfarin when 
they entered the trial. In a secondary analysis we did look at this transition at the 
conclusion of the trial separately to investigate whether the transition factor we 
found was similar to the calculated transition factor at the start of follow-up. 
We determined the maintenance dosage by calculating the mean dosage 
that led to three consecutive INRs within the therapeutic range, with at least 7 days 
between two INR checks. The maintenance dose was determined over the period 
closest to the transition date. For the first coumarin used this means the last 3 
consecutive INRs in range before switching. After the transition date we 
considered the first 4 weeks as a wash out period. So, for the second coumarin we 
searched for the first 3 INRs in range after the wash out period. All determined 
maintenance dosages were evaluated, and corrected if necessary, by an expert in 
anticoagulant dosing. Therapeutic ranges were as they are applied in our clinic: 
INR 2.0-3.5 for indications requiring a low intensity and INR 2.5-4.0 for high 
intensity. 
We performed linear regression analysis. All models were made with 
starting point at origin. Regression coefficients are given with their 95% 
confidence intervals. All calculations were performed using the statistical package 
SPSS version 14.0 (SPSS Inc, Chicago, Ill). 
 
Results 
In total 141 transitions were evaluated. Thirty-seven patients initiated their 
anticoagulant treatment with warfarin and switched to phenprocoumon. Eighty-
three patients were already treated with acenocoumarol and of these patients, 39 
switched to phenprocoumon and 44 to warfarin. Of these 44 patients randomized to 
a treatment with warfarin, 21 switched back to phenprocoumon at end of follow-
up. General characteristics of all patients are summarized in table 1. 
 




For 13 patients one of the maintenance dosages and for one patient both 
dosages could not be determined, because they did not have three consecutive 
INRs in range. The median maintenance dose of phenprocoumon for patients with 
a target range of 2.0-3.5 (n=68) was 2.09 mg/ day (interquartile range (IQR) 1.50- 
2.72). For acenocoumarol (n=58) and warfarin (n=81) the maintenance dose was 
2.46 mg/ day (IQR 1.79- 3.47) and 4.68 mg/ day (IQR 3.74- 6.60) respectively. 
Seventy-two patients (51.1%) were stable with their anticoagulant treatment at time 
of the transition, i.e. the last three INRs were within the therapeutic range. The 
median interval between the maintenance dose of the first coumarin and the second 
coumarin was 98 days (IQR 63- 153 days). 
 
Table 1. Patient characteristics 









Age    
 Median (IQR*) 69.5 (63.0 – 77.3) 67.0 (61.0-75.0) 66.0 (61.3-73) 
Sex    
 Men (%) 43 (74.1) 30 (76.9) 37 (84.1) 
Intensity of OAC    
 Low (2.0-3.5) (%) 51 (87.9) 26 (66.7) 33 (75.0) 
 High (2.5-4.0) (%) 7 (12.1) 13 (33.3) 11 (25.0) 
Indication for OAC    
 Atrial fibrillation 45 (77.6) 20 (51.3) 22 (50.0) 
 Venous thrombosis 5 (8.6) 2 (5.1) 6 (13.6) 
 Cardiac other 3 (5.2) 7 (17.9) 8 (18.2) 
 Peripheral arterial 4 (6.9) 7 (17.9) 6 (13.6) 
 Other 1 (1.7) 3 (7.7) 2 (4.5) 
*IQR=Interquartile range 
 
Transition from warfarin to phenprocoumon 
The first mean daily dose of phenprocoumon was 0.48 (95%CI 0.46-0.51) times 
the last mean daily dosage of warfarin. A loading dosage was given on the first day 
to 89.4% of the patients, and this loading dosage was approximately 1.6 times the 
mean daily dosage. 83.0% of patients received a loading dosage on the second day 
after transition and this was 2.3 times the mean daily dosage. A loading dose of 2.3 
times the mean daily dosage was given to 63.8% of patients on the third day after 




transition. Few patients (27.7%) received a loading dosage on the fourth day after 
transition and this was 2.1 times the mean daily dosage. In the wash out period of 4 
weeks after transition the median percentage time in the therapeutic range was 
62.8% (IQR 37.6 – 96.1). 
The transition factor between the maintenance dosage of phenprocoumon 
and warfarin in milligram was 0.41 (95% CI 0.39 – 0.43), indicating that the 
maintenance dosage of phenprocoumon is 0.41 times the maintenance dosage of 
warfarin (figure 2). 
 




















Figure 2. Relation between the maintenance dose of phenprocoumon and warfarin. 
 
 
Transition from acenocoumarol to phenprocoumon 
The first mean daily dose of phenprocoumon was 0.90 (95%CI 0.87-0.94) times 
the last mean daily dosage of acenocoumarol. A mean loading dosage of 2.5 times 
the mean daily dosage was given on the first day to 86.8% of the patients. On the 




second day 81.6% of the patients received a mean loading dosage of 3.3 times the 
mean daily dosage, and 63.2% of the patients was prescribed a mean loading dose 
of 2.5 times the mean daily dosage on the third day after transition. A small 
fraction of patients (5.3%) received a loading dosage on the fourth day after 
transition of approximately 2.0 times the mean daily dosage. The median 
percentage of time in the therapeutic range in the first four weeks was 69.5% (IQR 
49.9 – 94.7). 
The transition factor between acenocoumarol and phenprocoumon in 
milligram was 0.84 (95% CI 0.79 – 0.89), meaning that the maintenance dosage of 
phenprocoumon is 0.84 times the maintenance dosage of acenocoumarol (figure 3). 
























Figure 3. Relation between maintenance dosage of acenocoumarol and phenprocoumon 
 
Transition from acenocoumarol to warfarin 
The first mean daily dose of warfarin was 1.59 (95%CI 1.53-1.65) times the last 
mean daily dosage of acenocoumarol. A loading dosage was given on the first day 
to 82.9% of the patients, and this loading dosage was on average 1.8 times the 




mean daily dosage. 73.2% of the patients also received a loading dosage on the 
second day after transition and this was 1.8 times the mean daily dosage. A loading 
dose of 1.6 times the mean daily dosage was given to 36.6% of the patients on the 
third day after transition. Only one patient received a loading dosage on the fourth 
day after transition and this was 1.9 times the mean daily dosage. This led to a 
median percentage of time in therapeutic range in the first four weeks of 66.3% 
(IQR 48.4 – 95.8). 
The transition factor between the maintenance dosage of acenocoumarol 
and warfarin in milligram was 1.85 (95% CI 1.78 – 1.92), indicating that the 
maintenance dosage of warfarin is 1.85 times the maintenance dosage of 
acenocoumarol (figure 4). 





















Figure 4. Relation between maintenance dosage of acenocoumarol and warfarin 
 
All transition factors are listed in table 2. Age had minor effects on the transition 
factors. 




Table 2. Transition factors with corresponding 95% confidence intervals 
Direction of switch Transition factor 95% CI 
Warfarin to phenprocoumon 0.41 0.39 - 0.43 
Phenprocoumon to warfarin 2.36 2.24 - 2.48 
Acenocoumarol to phenprocoumon 0.84 0.79 – 0.89 
Phenprocoumon to acenocoumarol 1.15 1.08 – 1.22 
Acenocoumarol to warfarin 1.85 1.78 – 1.92 
Warfarin to acenocoumarol 0.53 0.51 – 0.55 
 
In table 3 the transition factors for different age categories are shown. The 
transition factors did not differ if we calculated them separately for the two 
different therapeutic ranges. There were minor differences in the transition factors 
for stable versus unstable anticoagulated patients which were not clinically 
relevant. 
 
Table 3. Transition factors with corresponding 95% confidence intervals for different age categories 
Direction of switch Agegroup N Transition 
factor 
95%CI 
Warfarin to phenprocoumon <66.7 21 0.40 0.37-0.42 
 66.7-74.3 21 0.42 0.38-0.37 
 >74.3 16 0.43 0.39-0.48 
 Total 58 0.41 0.39-0.43 
     
Acenocoumarol to phenprocoumon <66.7 17 0.83 0.74-0.93 
 66.7-74.3 12 0.83 0.76-0.90 
 >74.3 10 0.90 0.83-0.97 
 Total 39 0.84 0.79-0.89 
     
Acenocoumarol to warfarin <66.7 24 1.86 1.74-1.98 
 66.7- 74.3 13 1.84 1.73-1.94 
 >74.3 7 1.83 1.71-1.96 
 Total 44 1.85 1.78-1.92 
 
Of the patients who switched from acenocoumarol to warfarin 21 patients 
switched back to acenocoumarol at the conclusion of the trial. The transition factor 
between warfarin and acenocoumarol in these patients in milligram was 0.53 
(95%CI 0.50 – 0.56), which is approximately the same as the inverse of the 




transition factor we found in patients switching from acenocoumarol to warfarin at 
start of the trial (1/ 1.85 = 0.54). 
 
Discussion 
We investigated the transition factors between the maintenance dosages of the 
three frequently used coumarins for oral anticoagulant treatment. The maintenance 
dose of warfarin was 0.41 (95%CI 0.39- 0.43) times the maintenance dose of 
phenprocoumon. The transition factor between acenocoumarol and 
phenprocoumon was 0.84 (95%CI 0.79- 0.89) and between acenocoumarol and 
warfarin 1.85 (95%CI 1.78- 1.92). 
Because we had the unique situation of patients switching between 
warfarin, phenprocoumon and acenocoumarol within a randomized trial, i.e., 
without a medical reason to switch, we could study the relationship between the 
maintenance dosages of these three coumarins without bias. Also when we 
calculate the transition factor between phenprocoumon and warfarin by using the 
transition factors between acenocoumarol and phenprocoumon and acenocoumarol 
we find approximately the same result we observed in our patients (0.84/ 1.85 = 
0.45 versus 0.41). It should be noted that we investigated the relationship between 
the maintenance dosages; a transition scheme may also require a loading dose. We 
gave a description of our management during transition, but we did not investigate 
whether or not this was the most appropriate way to switch between coumarins. 
In some patients the time between the two maintenance doses was very 
long and we may question whether the dosages were still related to each other since 
the coumarin sensitivity may vary over time within a patient. However, since these 
variations are relatively small and random in their direction it is unlikely that this 
affected our results. This is also supported by the results of our secondary analysis 
where we found that in patients who switched from acenocoumarol to warfarin and 




back to acenocoumarol again the transition factor between acenocoumarol and 
warfarin is the same as the inverse of the transition factor between warfarin and 
acenocoumarol. 
In our study we found similar results as was found in the study of 
Kristiansen et al. [20]. They reported a transition factor of 2.3 for switching from 
phenprocoumon to warfarin, where we found a transition factor of 2.4. No 
literature is known about switching from acenocoumarol to phenprocoumon or 
from acenocoumarol to warfarin. Several studies showed that the variant alleles 
CYP2C9*2 or CYP2C9*3 are associated with an increased response to 
acenocoumarol and warfarin, whereas such an association is unclear for 
phenprocoumon [10, 21, 22]. These variant alleles could also interfere with the 
transition factors we presented in this manuscript. Unfortunately it was not possible 
to investigate this possible effect in our study population since the data were not 
available. We found minor differences in the transition factors for the different age 
categories which are not of clinical importance to our opinion. 
We calculated the transition factors between the maintenance dosages of 
the three most frequently used coumarins for oral anticoagulant treatment. With 
these transition factors physicians can easily determine the maintenance dosage 
when it is necessary for a patient to switch from one coumarin to another. 
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Introduction: Anticoagulants of the coumarin type are effective drugs for the 
treatment and prevention of thromboembolic diseases. However, they have a 
narrow therapeutic range and show interindividual and intraindividual variability in 
dose requirement, largely conditioned by both environmental and genetic factors.  
Methods: This prospective study investigated, during the initial phase of 
acenocoumarol therapy, the effect of CYP2C9 variant alleles and VKORC1 
haplotypes, single and in combination, in 220 Italians.   
Results: CYP2C9*3 was associated with a 25% dose reduction and an increased 
risk of over-anticoagulation (INR>6) on day 4. Two copies of the VKORC1*2 
haplotype were associated with a 45% dose reduction and an increased risk of over-
anticoagulation. Homozygosity for VKORC1*3 and VKORC1*4 was associated 
with an increased dose requirement and a reduced risk of over-anticoagulation. The 
VKORC1*3 or *4 plus CYP2C9*1 genotype combination was associated with the 
highest dose requirement and the lowest INR on day 4; VKORC1*2 plus 
CYP2C9*3 was associated with the lowest dose requirement, the highest INR and 
an increased risk of over-anticoagulation. Even though they spent approximately 
50% of the time within the target therapeutic range, VKORC1*3 or *4 plus 
CYP2C9*1 carriers spent a large percentage of the remaining time below and 
carriers of VKORC1*2 plus CYP2C9*3 above the target range.  
Discussion: The determination of VKORC1*3 and VKORC1*4 haplotypes may be 
an important addition to CYP2C9 and VKORC1*2 genotyping to identify patients 









Anticoagulant drugs play an important role in the prophylaxis and treatment of 
thrombotic events, and are widely used chronically or intermittently in 
cardiovascular medicine and surgery [1]. For instance, their use has decreased the 
risk of thrombotic events and death due to acute myocardial infarction by 24% [2] 
and 80%, respectively [3]. However, the use of vitamin K (VitK) antagonists as 
oral anticoagulants still poses significant clinical challenges because their 
therapeutic index is narrow and dose-response relationship unpredictable [4]. The 
latter situation makes difficult to predict the daily maintenance dose, that for 
warfarin may range from as little as 0.5 to as much as 60 mg [5] and for 
acenocoumarol from 1 to 56 mg [6]. These large variations in dose requirements, 
influenced by pharmacokinetic and pharmacodynamic aspects in turn determined 
by genetic and environmental factors, demand frequent measurements of the 
International Normalized Ratio (INR) of the prothrombin time to evaluate the 
degree of anticoagulation and to assess the need for dosage changing.  
Warfarin is the main vit.K antagonist prescribed in the United Kingdom 
and North-America, while acenocoumarol, the 4’nitro-analogue of warfarin, is 
widely used in European countries. Elimination of the two acenocoumarol isomers 
depends entirely on their hepatic biotransformation by the CYP2C9 enzyme [7, 8]. 
Carriers of genetic polymorphisms of CYP2C9, in particular of the CYP2C9*2 and 
CYP2C9*3 variant alleles [9-10], require smaller doses of acenocoumarol than 
carriers of the most frequent 2C9*1 wild-type allele and have a higher incidence of 
minor bleeding episodes [11], even though dose-effect association for the 
CYP2C9*2 variant allele was not consistently found [6, 11-17]. The CYP2C9*3 
variant allele is also associated with a reduced likelihood to achive stability within 
the target INR range during the first 6 months of acenocoumarol use and with an 
increased risk of severe anticoagulation (INR>6) [14].  




Oral anticoagulants exert their effect by reducing the regeneration of Vit.K 
from its epoxide through the inhibition of Vit.K epoxide reductase [18]. This 
protein is coded by the Vit.K epoxide reductase complex subunit 1 gene 
(VKORC1) [19-20]. Several polymorphisms in the VKORC1 gene are mainly 
located in non-coding regions and are in strong linkage disequilibrium (LD), so 
that a few of them are enough to infer the most common haplotypes that explain 
the genetic variability of VKORC1 [21, 22]. Rieder et al., [21] divided the most 
common haplotypes in two main groups: group A (haplotypes H1 and H2), 
associated with low warfarin dose requirement and the group B (haplotypes H7-
H9), associated with an increased dose requirement. Geisen et al., [22] later 
described three haplotypes (VKORC1*2, VKORC1*3, VKORC1*4) covering 
>99% of the genetic variability in Europeans: the VKORC1*2 haplotype 
(corresponding to group A) was strongly associated with an increased coumarin 
sensititity whereas VKORC1*3 and VKORC1*4 (both included into group B) with  
partial resistance. Even though the combined effect of both VKORC1 and CYP2C9 
on warfarin [21, 23- 27] was fully investigated, less information is available on 
acenocoumarol response [15, 28-30]. Thus, this prospective study was designed to 
investigate the  contribution of the common CYP2C9 variant alleles and VKORC1 
haplotypes in the modulation of acenocoumarol response. We chose to investigate 
the initial phase of treatment because the first months are particularly problematic, 
since the safe and effective dose for an individual patient is not known and is 
determined empirically, with an increased risk of over-anticoagulation and 
hemorrhagic complications [31]. Our primary purpose was to evaluate the effect of 
the CYP2C9 variant alleles and VKORC1 haplotypes and of their combination on 
the first INR determination and on mean weekly acenocoumarol dosages. The risk 
of severe over-anticoagulation (defined as INR>6) at the time of the first INR 




determination and the percentage of time spent below, within and above the target 




The study cohort of North-Italian patients was prospectively recruited at two 
anticoagulant clinics in Milan: the Istituto Clinico Humanitas and San Paolo 
Hospital. Included were patients aged 18 years or more who started oral 
anticoagulant therapy with acenocoumarol for arterial or venous thrombosis or 
non-ischemic heart disease (atrial fibrillation and dilatative cardiopathy). Exclusion 
criteria were the presence of concomitant severe diseases known to interfere with 
this treatment (i.e. liver cirrhosis, uremia, malignant diseases). All patients started 
treatment with the same standard dosage of acenocoumarol during the first 3 days 
of therapy (4 mg, 4 mg, 2 mg), the first INR being scheduled on day 4 and 
subsequently once or twice weekly. Acenocoumarol dosing was based on a 
computerized system (Parma 4.1) which includes an algorithm that recommends 
the therapeutic dose [32]. Demographic data, indication for anticoagulant therapy, 
INR target range, concomitant disease, co-medications, diet (vegetarian or not) and 
bleeding episodes were collected. The daily acenocoumarol doses administered 
during the initial phase of treatment (arbitrarily set at 52 days, i.e., first 3 days plus 
7 weeks) and INR values obtained during control visits at the clinic were also 
collected. All patients gave written informed consent for analysis of their DNA. 
The study protocol was approved by the Medical ethics Committee of the 
participating hospitals  
 





Venous blood was collected in sodium citrate 0.105 M. Plasma and cells were 
separated after centrifugation at 4000 g for 30 min. DNA was isolated from 
leukocytes using the salting out method [33]. The INRs (International Normalized 
Ratio) were performed in all centers using the same reagent/instrument 
combination, namely, human recombinant thromboplastin (RecombiPlasTin, 
HemosILTM, INstrumentation Laboratory Company, USA), and a Electra 1600 
coagulometer (IL, Milan, Italy). All the participating centers performed regular 
external quality control exercises. 
 
Genotyping 
The polymerase chain reactions and endonuclease digestions were used for the 
detection of the CYP2C9*2 (c.430 C/T, rs1799853) and 2C9*3 (c.1075 A/T, 
rs1057910) variant alleles [34]. Three polymorphisms located at the VKORC1 
gene, i.e. c.173+1000 C/T (rs9934438) in intron 1 and c.492+134 G/A (rs7294) in 
the 3'UTR, both previously identified by D’Andrea et al., [35] and c.173+525 C/T 
(rs17708472) were analysed. For the analysis of VKORC1 c.173+1000 C/T a sense 
(5’-TGACATGGAATCCTGACGTG -3’) and antisense (5’-GAGCTGACCAA-
GGGGGAT-3’) PCR primers and HinfI restriction enzyme (New England 
BioLabs) were used; for the c.492+134 G/A a sense (5’-ATGGAGTGTTCGGG-
AGGTG-3’) and antisense (5’-ACAGTCCATGGCAGACACAT-3’) PCR primers 
and AciI restriction enzyme (New England BioLabs), and for that of the c.173+525 
C/T a sense (5’-CGTTAGCATAATGACGGAATACAG-3’) and antisense (5’-
AACTCCTGACTTCAAGTGATCCAT-3’) PCR primers and BfaI restriction 
enzyme (New England BioLabs) were used, respectively. 
The analysis of the combination of these polymorphisms allow to establish 
for each patient the presence of the VKORC1*1 haplotype, (the putative ancestral 




haplotype, characterized by the presence of the normal alleles: c.173+1000 C, 
c.492+134 G and c.173+525 C polymorphisms [22]), the VKORC1*2 haplotype 
(characterized by the presence of the variant allele c.173+1000 T and the normal 
alleles: c.492+134 G and c.173+525 C [22]), the VKORC1*3 haplotype 
(characterized by the presence of the variant allele c.492+134 A and the normal 
alleles: c.173+1000 C and c.173+525 C [22]), and the VKORC1*4 haplotype 
(characterized by the presence of the variant allele c.173+525 T and the normal 
alleles: c.173+1000 C and c.492+134 G [22]). 
 
Statistical analysis 
Continuous variables, expressed as mean (range) were used for age, body surface 
area (BSA), days of follow-up, INR range, INR values and administered daily 
doses. BSA was calculated according to the formula: 0.00718 x height0.725 x 
weight0.425 [36]. In each patient the doses of acenocoumarol, administered after the 
first 3 days of standard dosages (4 mg, 4mg, 2 mg), were calculated for weekly 
periods (day 4-10, day 11-17, day 18-24, day 25-31, day 32-38, day 39-45, day 45-
53). In order to analyze the effect of age on dose requirement, age at the start of 
therapy was divided into seven 10-year categories, the lowest ranging from years 
20 to 30 and the highest from years 80 to 90. Dummy variables were used to code 
for sex, clinical variables (indications for acenocoumarol, presence of concomitant 
diseases) and concomitant medications. In order to quantify how a single copy or 
two copies of each CYP2C9 or VKORC1 variant alleles affect acenocoumarol dose 
requirement (according to a additive allelic effect), dummy variable codes were 
established. As regards CYP2C9, 0 was assigned to carriers of two copies of the 
CYP2C9*1 wild-type allele, 1 to carriers of one copy of the CYP2C9*2 variant 
allele, 2 to carriers of two copies of the CYP2C9*2 variant allele, 3 to carriers of 
one copy of the CYP2C9*3 variant allele, 4 to carriers of both CYP2C9*2 and  




CYP2C9*3 variant alleles and 5 to carriers of two copies of the CYP2C9*3 variant 
allele. Patients were then divided into groups according to the presence of two 
wild-type alleles (code: 0), at least one CYP2C9*2 variant allele (heterozygous or 
homozygous, code: 1) or at least one CYP2C9*3 variant allele (heterozygous or 
homozygous, code: 2). Heterozygotes for the 2C9*2/*3 genotype were grouped 
only with patients carrying at least one 2C9*3 variant allele. 
As regards VKORC1, 0 was assigned to carriers of two copies of the 
VKORC1*1 ancestral  haplotype, 1 to carriers of one copy of the VKORC1*3 
haplotype, 2 to carriers of one copy of the VKORC1*4 haplotype, 3 to carriers of 
two copies of the VKORC1*3 haplotype, 4 to carriers of both VKORC1*3 and 
VKORC1*4 haplotype, 5 to carriers of two copies of the VKORC1*4 haplotype, 6 
to carriers of both VKORC1*2 and VKORC1*3 haplotype, 7 to carriers of both 
VKORC1*2 and VKORC1*4 haplotype, 8 to carriers of one copy of the 
VKORC1*2 haplotype and 9 to carriers of two copies of the VKORC1*2 
haplotype. The ascending number of the dummy variable codes was assigned to 
each genotype according to the increased reported effect of the variant alleles on 
coumarin response [22]. Each group was compared with the wild-type group. 
Finally, patients were divided according to the possible CYP2C9 and VKORC1 
genotype combinations.  
In order to analyze the effect of CYP2C9 variant alleles and VKORC1 
haplotypes on dose requirement during the first 7 weeks of therapy, only patients 
with target INR between 2.0 and 3.0 were considered, while patients with a 
different INR target were excluded from this analysis. To analyze the effect of 
CYP2C9 variant alleles and VKORC1 haplotypes on the first INR, only patients 
who had INR measured on day 4 of treatment were considered. 
For comparison of the mean INR value on day 4 of therapy and the mean 
dose requirement during the first 7 weeks of therapy between single and combined 




genotypes, one-way ANOVA tests with post-hoc multiple comparison adjustments 
(Bonferroni for equal variance or Dunnett T3 for non-equal variance) were 
performed. A multivariate linear regression model was used to assess the 
independent effect of genetic factors and other environmental variables on the first 
INR estimate and dose requirement. Relative risks (RR) with 95% confidence 
interval (CI) were calculated to compare the proportion of patients with INR>6 
(severe over-anticoagulation) for single and combined genotypes. Finally, for each 
genotype combination, the percentage of time (days) spent within, above and 
below the INR target range during the first 7 weeks of therapy were evaluated 
using the linear interpolation method described by Rosendaal et al. [37]. One-way 
ANOVA tests with post-hoc multiple comparison adjustments (Bonferroni for 
equal variance or Dunnett T3 for non-equal variance) were performed to assess the 
differences in percentages between genotype combinations. 95% confidence 
intervals (CI) were used to indicate the significance of each test. All statistical 




Between 2003 and 2005, 220 Italian patients (all Caucasians) meeting the inclusion 
criteria were enrolled in the study. Patient characteristics are summarized in Table 
1. Two hundred and one (91.4%) completed the scheduled follow-up of 53 days, 
whereas 19 did not complete follow up or stopped therapy for various reasons. 
Allele and genotype frequencies for the CYP2C9*2 and CYP2C9*3 variant alleles 
and for the different VKORC1 haplotypes are summarized in Table 2. None of the 
patients was homozygous for the reference VKORC1*1 haplotype.  




Table 1. Characteristics of patients 
  
Number of patients 220
Age, years [mean,(range)] 65 (23 – 87) 
Gender, n (%) 
Male 133 (60.5) 
Female 87 (39.5) 
BSA, m2 [mean, (range)] 1.84 (1.36-2.48) 
Follow-up, days [median, (range)] 53 (6 - 53) 
Indication for anticoagulant  therapy, n (%):
Arterial thrombosis* 39 (17.7) 
Venous thrombosis** 57 (25.9) 
Non-ischemic cardiac disease*** 124 (56.4) 
Target INR, n (%):
1,8 – 2,2 1 (0.5) 
1,8 – 2,5 1 (0.5) 
2,0 – 2,5 2 (0.9) 
2,0 – 3,0 187 (85.0) 
2,5 – 3,5 28 (12.7) 
2,5 – 5,0 1 (0.5) 
Concomitant diseases, n (%):
cardiovascular risk factors 73 (33.2) 
history of arterial thrombosis 17 (7.7) 
history of venous thrombosis 4 (1.8) 
benign tumors 7 (3.2) 
diseases associated with haemorragic risk 2 (0.9) 
venous insufficiency of the lower limb 2 (0.9) 
Concomitant medications, n (%):
Drugs known to increase the INR 44 (20.0) 
Drugs known to decrease the INR 17 (7.7) 
Drugs with unknown effect on INR 109 (49.5) 
* Arterial thrombosis includes acute coronary syndromes, stroke, TIA, peripheral arterial emboli 
** Venous thrombosis includes deep vein thrombosis and pulmonary embolism  
*** Non-ischemic cardiac disease includes atrial fibrillation and dilatative cardiomyopathy 
 
Table 2. Genetic characteristics of patients 
Polymorphism Allele % Genotype N % 
CYP2C9 *1 76.1 *1/*1 132 60.0 
 *2 14.8 *1/*2 48 21.8 
 *3 9.1 *1/*3 25 11.4 
 *2/*2 6 2.7 
 *3/*3 4 1.8 
   *2/*3 5 2.3 
VKORC1 *1 3.35 *1/*1 0 0 
 *2 42.63 *1/*3 8 3.6 
 *3 36.16 *1/*4 4 1.8 
 *4 17.86 *3/*3 a 29 13.2 
 *3/*4 32 14.5 
 *4/*4 d, e 6 2.7 
 *2/*3 60 27.3 
 *2/*4 30 13.6 
 *1/*2 3 1.4 
   *2/*2 b, c 48 21.8 
a 1 patient was VKORC1 *3/*3 homozygous + *1/*4 heterozygous, b 1 patient was VKORC1 *2/*2 homozygous + *1/*3 
heterozygous, c 1 patient was VKORC1 *2/*2 homozygous + *1/*4 heterozygous, d 2  patients were VKORC1 *4/*4 homozygous 
+ *1/*2 heterozygous, e 3 patients were VKORC1 *4/*4 homozygous + *1/*3 heterozygous 




Effect of single CYP2C9 alleles and VKORC1 haplotypes on the first INR value  
This effect was evaluated only in patients (n=164, 74.5%) who had their INR 
measured on day 4 of treatment. Table 3 shows that carriers of at least one 
CYP2C9*3 variant allele had a higher mean first INR than CYP2C9*1/*1 wild-
type patients, the highest INR being observed for the homozygous CYP2C9*3/*3 
genotype [5.6; range: 3.2-10.0; 95%CI of difference vs wild-type patients: -7.68 - 
2.14]. The presence of at least one CYP2C9*2 variant allele resulted in a higher 
INR than that of wild-type patients too.  
As the reference VKORC1*1/*1 genotype was not represented, each 
VKORC1 genotype was compared to VKORC1*2 homozygotes, being the 
VKORC1*2 haplotype associated with the larger INR variation and the lower 
warfarin maintenance doses [38]. Homozygotes for the VKORC1*2 haplotype had 
the highest mean first INR compared to all the other genotypes (Table 3). 
Homozygotes for the VKORC1*3 haplotype had no difference in mean INR values 
on day 4 compared to homozygotes for the VKORC1*4 haplotype (2.6; range: 1.4-
7.7 vs 2.4, range: 1.4-3.6; 95%CI of diff: -2.14 – 2.32). Heterozygous combinations 
of the VKORC1*3 or VKORC1*4 haplotypes seem to have at least equal impact 
on the INR value on day 4 as homozygosity for either VKORC1*3 or VKORC1*4. 
On the other hand, also VKORC1*1/*2 heterozygotes had higher mean first INR.  
The risk of early over-anticoagulation (INR >6 on day 4) associated with 
the presence of variant alleles was evaluated in comparison to CYP2C9*1/*1 
homozygotes and to homozygotes for the VKORC1*2 haplotype. Table 3 shows 
that carriers of at least one CYP2C9*2 or CYP2C9*3 variant allele had 3.39 and 
2.81 times higher risks of over-anticoagulation. The highest risk (6.58 times) was 
found for CYP2C9*3/*3 homozygotes (95%CI: 0.93 - 45.45). The homozygous 
VKORC1*2/*2 genotype was characterized by the highest number of INR>6 on 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Sex, indication for therapy, concomitant diseases, medications and BSA 
did not affect the first INR. Age at start of therapy was positively associated with 
the first INR, but was not a confounding factor for the association between 
genotype and first INR. Multiple linear regression analysis showed that both 
CYP2C9 and VKORC1 genotypes separately influenced the first INR value on day 
4 of therapy and that, together with age, they explain 26% of the observed INR 
variability. 
 
Effect of single CYP2C9 alleles and VKORC1 haplotypes on dose requirement 
during the first 7 weeks of therapy 
This effect was evaluated in 187 patients (85%, only patients with a target 
INR=2.0-3.0). Table 4 shows that carriership of at least one CYP2C9*2 allele was 
associated with a lower mean weekly dose compared to patients carrying only the 
wild-type allele. The decrease varied from 9% in the first week (1.3 mg) to 17%  in 
the 7th week (3.13 mg). Carriership of at least one CYP2C9*3 variant allele 
decreased to a greater degree than CYP2C9*2 the weekly dose compared to wild-
type patients, i.e. from 22% in the first week of therapy (3.1 mg) to 25% in the 7th 
week (4.8 mg). 
              Homozygosity for the VKORC1*2 haplotype was associated with a lower 
mean weekly dose compared to the other VKORC1 genotypes, particularly in 
comparison with carriers of the homozygous VKORC1*3 haplotype, the decrease 
varying from 41% in the first week (6.5 mg) to 49% in the 7th week (11.1 mg), and 
with carriers of the homozygous VKORC1*4 haplotype, the decrease being around 
40% all along the first seven weeks (~ 7 mg). Homozygotes for the VKORC1*3 
and VKORC1*4 haplotypes showed no differences in the required mean weekly 
doses [95% CI: -22.59 – 29.92 at week 7]. All the other VKORC1 genotypes 
required mean weekly doses in the range between those required by 




VKORC1*2/*2 and VKORC1*3/*3.   
              Concomitant medications and diseases were not associated with dose 
requirement, whereas BSA, age, sex and indication for therapy were associated 
factors but not confounders for the association between genotype and dose 
requirement. Multiple linear regression analysis showed that CYP2C9 and 
VKORC1 genotypes, together with sex, BSA, age at the start of therapy and 
indication for therapy, accounted for 20% of the observed variability in dose 
requirement in the first week of therapy. The influence of these factors increased 
over the following weeks and in the 7th week they accounted for 27% of the 
variability. The major role on variability was exerted by VKORC1, that in the 7th 
week of therapy accounted for 12% of it, followed by CYP2C9 genotype (5%). 
 
Effect of CYP2C9 and VKORC1 combinations on the first INR value 
Only patients homozygous for the VKORC1*2, VKORC1*3 and VKORC1*4 
haplotypes were considered. As VKORC1*3 and VKORC1*4 haplotypes showed 
no differences in the first INR and dose requirement, homozygous carriers of these 
haplotypes were combined. In each of the VKORC1*2 and VKORC1*3 or *4 
groups, the effect of the CYP2C9*2 and *3 variant alleles were investigated.  
 
Table 5. Frequency of the combinations between homozygous VKORC1*2 and VKORC1*3 or VKORC1*4 
haplotypes and CYP2C9 alleles in the whole cohort of patients. 
 
GENOTYPE COMBINATION N of patients from the whole cohort % 
N of patients with 
target INR of 2.0-3.0 % 
VKORC1*2 + CYP2C9*1  31 37.4 27 37 
VKORC1*2 + CYP2C9*2 11 13.3 9 12.3 
VKORC1*2 + CYP2C9*3 6 7.2 5 6.8 
VKORC1*3 or *4 + CYP2C9*1 19 22.9 18 24.7 
VKORC1*3 or *4 + CYP2C9*2 9 10.8 7 9.6 















The frequency of each genotype combination in the whole cohort of 
patients is shown in Table 5. 
Figure 1 shows the first INR in patients with different VKORC1 and 
CYP2C9 genotype combinations. Among carriers of VKORC1*2, associated with 
the highest mean INR on day 4, the presence of the CYP2C9*3 variant allele, but 
not that of the CYP2C9*2 variant allele, increased the mean INR on day 4 
compared to carriers of the CYP2C9*1 wild-type allele [5.9; range: 3.6–10.0 vs 
4.1; range: 2.2-6.6; 95%CI of diff: -0.36 – 3.99]. The CYP2C9*3 variant allele was 
also associated with a 5 times increased risk of INR>6.0 [95%CI: 1.07–23.26] 
compared to the CYP2C9*1 wild-type allele.  
 
 
Figure 1. Box plot of first INR values on day 4 of acenocoumarol and therapy in patients with different C4P2C9 and VKORC1 
genotype combinations. 
 
Among carriers of VKORC1*3 or VKORC1*4, the presence of  both the 
CYP2C9*2 and CYP2C9*3 variant alleles did not affect the mean INR on day 4 
compared to carriers of the CYP2C9*1 wild-type allele  [3.3; range: 1.5-7.8 vs 2.2; 




range: 1.4-3.6; 95%CI of diff: -1.18 – 3.34 and 2.7; range: 1.4-3.6 vs 2.2; range: 
1.4-3.6; 95%CI of diff: -1.92 – 2.91,  respectively].  
 
Effect of CYP2C9 and VKORC1 combinations on weekly dose requirement 
Weekly dose requirement was compared only in patients with target INR 
of 2.0 to 3.0 (n=73). The doses of acenocoumarol required by patients with 
different CYP2C9 and VKORC1 genotype combinations in the first 7 weeks of 




Figure 2. Mean acenocoumarol doses (mg/week, ± SD) required by patients with different genotype combinations during the first 
7 weeks of therapy 
 
Among carriers of VKORC1*2, associated with the lowest mean weekly 
dose requirement, the presence of the CYP2C9*2 variant allele decreased the mean 
dose required during the first weeks of therapy compared to carriers of CYP2C9*1. 
The extent of the reduction ranged from 18% (1.7 mg, 95%CI of diff: -1.48 – 4.89) 
during the 1st week of therapy to 27% (3.3 mg, 95%CI of diff: -1.95 – 8.51) during 
the 7th week of therapy. The presence of the CYP2C9*3 variant allele also 
decreased the required mean weekly dose compared to CYP2C9*1. The decrease 




ranged from 25% (2.6 mg, 95%CI of diff: -2.25 – 7.35) during the 1st week of 
therapy to 14% (1.8 mg, 95%CI of diff: -11.2 – 14.78) during the 7th week of 
therapy. 
Among carriers of VKORC1*3 or VKORC1*4, associated with the highest 
mean weekly dose requirement, the presence of the CYP2C9*2, compared to 
carriers of CYP2C9*1, decreased the dose requirement from 3.4% (0.6 mg, 95%CI 
of diff: -7.25 – 8.46) during the 1st week of therapy to 12% (2.4 mg, 95%CI of diff: 
-10.68 – 15.43) during the 7th week of therapy. The presence of the CYP2C9*3 
variant allele also decreased the mean weekly dose required from 7.4% (2.6 mg, 
95%CI of diff: -6.98 – 9.33) during the 1st week of therapy to 23% (5.4 mg, 95%CI 
of diff: -6.48 – 17.2) during the 7th week of therapy.  
 
In all, carriers of both the VKORC1*3 or *4 allele and the CYP2C9*1 wild-type 
allele had the lowest mean INR on day 4 of therapy and required the highest mean 
weekly dose during the first weeks of therapy (Figure 1 and 2), while carriers of 
both VKORC1*2 and CYP2C9*3 alleles had the highest mean INR on day 4 and 
required the lowest mean weekly dose during the first weeks of therapy. Compared 
to the former, they had roughly 3 times higher mean INR [5.9 vs 2.2; 95%CI of 
diff.: 1.48 – 5.99], and required an average 55% lower mean weekly dose (~ 10.5 
mg) of acenocoumarol [95%CI of diff.: 2.89 – 14.545 at week 1; -0.83 – 26.38 at 
week 7].  
 
Effect of CYP2C9 and VKORC1 combinations on the percentage of time spent 
within, below or above the INR target range  
The mean percentages of time spent within, above and below the INR target range 
were evaluated for each genotype combination. Table 6 shows that carriers of all 
the combinations spent approximately 50% of the initial phase of treatment in the 




target range. However, among carriers of VKORC1*2, carriers of the CYP2C9*3 
variant allele spent a higher percentage of time above their target range than 
carriers of CYP2C9*1 allele and a smaller percentage of time below it. Among 
carriers of VKORC1*3 or *4, the presence of the CYP2C9*2 or CYP2C9*3 
variant alleles had the same effect, increasing the mean percentage of time spent 
above their target range compared to carriers of the CYP2C9*1 allele and 
decreasing the percentage of time spent below it.  
 
Table 6. Mean and range of the percentage of time spent in, below or above the INR target range by carriers of 
different VKORC1 and CYP2C9 genotype combinations. The means, the p-value and 95% confidence intervals 
(CI) were evaluated taking as references the VKORC1*2 + CYP2C9*1 and the VKORC1*3 or *4 + CYP2C9*1 




% days spent  
in the INR target 
range 
% days spent  
below the INR 
target range 
% days spent  





Mean 48.8 19.0 32.3
Range 20 - 92 0 - 62 0 - 73 







Mean 47.7 22.6 29.7
Range 20 - 70 3 – 58 0 – 74 







Mean 49.1 9.0 41.9
Range 15 - 85 0 - 25 5 - 85 
p; [95%CI] 1.00 [-41.98 – 41.35] 0.67 [-9.87 – 29.78] 1.00 [-40.83 – 21.54] 





Mean 50.0 41.5 8.5
Range 0 – 85 0 - 100 0 - 50 
p; [95%CI] ref ref ref





Mean 58.3 21.0 20.8
Range 4 - 100 0 - 62 0 - 96 
p; [95%CI] 0.99 [-45.74 – 29.31] 0.4 [-10.42 – 51.47] 1.0 [-40.60 – 15.98] 





Mean (SD) 54.9 24.6 20.4
Range 38 - 78 3 - 58 0 - 51 
p; [95%CI] 1.0 [-27.72 – 17.90] 0.67 [-15.09 – 48.80] 1.0 [-42.86 – 18.96] 




Finally, compared to carriers of the VKORC1*3 or *4 plus CYP2C9*1 
alleles combination, a lower percentage of time spent below the target range was 
found in carriers of the VKORC1*2  plus CYP2C9*3 combination  (9.0%, range: 
0-25 vs 41.5, range: 1-100; 95%CI of diff: 8.4 – 56.6). They also spent a higher 
percentage of time above the target range [41.9%; range:5–85 vs 8.5, range: 0-50; 
95%CI of diff: 0.70 – 66.12], in accordance with the correspondingly lower 
acenocoumarol doses required during the same period and the higher mean INR on 
day 4.  
 
Exclusion of patients taking concomitant medications known to increase (n= 44) or 
decrease (n= 17) the INR did not significantly change the observed effect of 
VKORC1 and CYP2C9. The outcomes of the effect of the VKORC1 and CYP2C9 
genotype combinations on dose requirement, as well as their effect on the first INR 
value, the risk of severe over-anticoagulation and the percentage of time spent 
within, below or above the INR target range remained the same, with no loss of 
statistical significance. The results of the single CYP2C9 variant alleles and 
VKORC1 haplotypes on the risk of severe over-anticoagulation also remained the 
same. For the outcomes of the effect of single CYP2C9 variant alleles on dose 
requirement, statistical significance for the difference between carriers of at least 
one CYP2C9*3 variant allele compared to carriers of only wild-type allele was lost 
(95%CI: -1.09 – 6.23 at week 1; 95%CI: -0.17 – 1.09 at week 7). For the outcomes 
of the effect of single VKORC1 haplotypes on the first INR value, significance for 
the difference between carriers of the homozygous VKORC1*4/*4 haplotype 
compared to carriers of the homozygous VKORC1*2/*2 haplotype was lost 
(95%CI: -0.17 – 4.28). The same occurred for carriers of the heterozygous 
VKORC1*2/*4 haplotypes (95%CI: -0.60 – 3.33). 
 
 





This study was planned and performed to evaluate the effect of all the common 
gene variants, previously identified as modifiers of oral anticoagulant therapy with 
vit.K antagonists, on the initial phase of administration of acenocoumarol, a drug 
that was studied so far less than warfarin in terms of pharmacogenetics. The initial 
phase of treatment was chosen as the most critical and unstable, thereby 
engendering a risk of both over-anticoagulation (and hence of bleeding) and under-
coagulation (and of thrombosis).  
The first finding of this study is that, pertaining to the effect of the CYP2C9 
gene, only the CYP2C9*3 variant allele plays an important modifying role during 
the first 7 weeks of treatment, because its presence significantly reduces the 
required dose of acenocoumarol and increases the risk of over-anticoagulation 
(INR>6) on day 4 of treatment, particularly for homozygotes[12-17]. This result is 
in agreement with Bodin et al., [28] and Schalekamp et al.,[29], the latter being the 
only study that analysed the effect of both VKORC1 and CYP2C9 genotypes during 
the initial phase of acenocoumarol treatment. However, our finding is in contrast 
with Gonzàlez-Conejero et al., [30], who reported that CYP2C9 polymorphisms 
have no effect on the first INR value after 3 days of acenocoumarol therapy. This 
discrepancy might be due to the fact that Gonzàlez-Conejero et al., performed the 
analysis combining together CYP2C9*2 and CYP2C9*1 carriers. 
Pertaining to the VKORC1 gene, the presence of the ancestral VKORC1*1 
haplotype [22] was found at a low frequency in our Italian population, in contrast 
with Geisen et al., [22] and Osman et al., [38], who showed that this haplotype is 
absent in European populations. Interestingly, a rare VKORC1 mutation,  p.D36Y, 
previously identified in individuals who required an average warfarin dose greater 
than 10 mg/day [39], was recently reported to tag a unique haplotype found on a 
VKORC1*1 background in Ashkenazi and Sephardi Jews [40]. Replication studies 




on other Caucasian populations are thus required to establish the real frequency of 
this allele.  
Homozygotes for the VKORC1*2 haplotype required the lowest 
acenocoumarol doses and had a 4.5 times increased risk of over-anticoagulation 
(INR>6) on day 4 compared to homozygotes for the VKORC1*3 or VKORC1*4 
haplotypes. Both these haplotypes had a similar effect on INR and dose 
requirements, being associated with higher acenocoumarol doses and lower INR on 
day 4. This confirms the findings of Osman et al., [38] in warfarin-treated patients. 
The VKORC1*2 haplotype is characterized by the presence of the c.173+1000 C/T 
polymorphism, which is in complete linkage disequilibrium with the promoter 
polymorphism c.-1639G/A, that re-establishes a E-box consensus sequence 
reducing the promoter activity and thus VKORC1 mRNA expression [41]. The 
VKORC1*3 haplotype is characterized by the presence of the c.492+134 G/A 
polymorphism, first identified by D'Andrea et al., [35] in Italian patients on 
warfarin therapy, and then described by Geisen at al. [22] to be associated with a 
partial resistence to warfarin. As expected from the effect of single alleles, the 
highest dose requirement and the lowest INR on day 4 were found for the 
homozygous VKORC1*3 or *4 plus CYP2C9*1 genotype combination, whereas 
the lowest doses, the highest INR as well as an increased risk of over-
anticoagulation were for the VKORC1*2 plus CYP2C9*3 genotype combination. 
Moreover, in the initial phase of therapy patients carrying all the investigated 
CYP2C9 and VKORC1 combinations spent the same amount of time in the INR 
therapeutic range. Carriers of VKORC1*3 or *4 plus CYP2C9*1, associated with a 
greater resistance to acenocoumarol, spent a large percentage of the remaining time 
below the target range, whereas carriers of the VKORC1*2 plus CYP2C9*3 
combination, associated with a higher sensitivity to the drug, spent a greater amount 
of the remaining time above the target range. This is in agreement with Schalekamp 




et al., [29], who reported that only carriers of a combination of CYP2C9 and 
VKORC1 C1173T polymorphisms have a high risk of over-anticoagulation.  
Therefore, based on the obtained results we could conclude that it may be 
necessary to test not only the CYP2C9 genotype (particularly the CYP2C9*3 
variant allele) and the VKORC1 c.173+1000 C/T polymorphism (VKORC1*2 
haplotype), but also the VKORC1 c.492+134 G/A (VKORC1*3) and the c.173+525 
C/T (VKORC1*4) to identify patients with the extreme phenotypes: those with a 
higher sensitivity to acenocoumarol and  more exposed to the risk of over-
anticoagulation (bleeding); those with a greater resistance to the drug are more 
exposed to the risk of under-anticoagulation (thrombosis), particularly in the initial 
phase of treatment.  
To our knowledge this is the first work that take into consideration the effect of the 
VKORC1*3 and VKORC1*4 haplotypes other than that of VKORC1*2 in the 
initial phase of acenocoumarol therapy. 
The CYP2C9 and the VKORC1 genotypes, together with age, explain 26% 
of the observed INR variability. They also account -- together with sex, BSA, age 
and indications for non-ischemic cardiac disease or venous thrombosis -- for 27% 
of the variability in dose requirement observed on the 7th week of therapy. In both 
situations, our results confirm that a major role is exerted by VKORC1, followed by 
CYP2C9 genotype [23, 28-29]. The variability explained in this study is lower that 
the variability explained in the warfarin response [42]. These differences might be 
due to  different study design and all variants included in the model, as well as to 
other unknown genetic and non-genetic variables not considered in this study. 
Our study also included also some patients treated with other medications 
known to interfere with the effect of the anticoagulant drug, with the possibility to 
affect the results and this seems to be a limit of the study design. However, the 
regression analysis adjusted for these risk factors did not change the effect of the 




CYP2C9 and VKORC1 genotypes. The same study design was also used in previous 
reported studies [15, 29, 31, 43-45]. Moreover, the effect of CYP2C9 and VKORC1 
genotypes was also confirmed after the exclusion of these patients from the 
analysis. 
 
A limit of the study is that our cohort includes also some patients treated with other 
medications known to interfere with the effect of the anticoagulant drug, with the 
possibility to affect the results. However, the same study design was used in other 
studies [15, 29, 31, 43-45] and the effect of CYP2C9 and VKORC1 genotypes was 
also confirmed after the exclusion of these patients from the analysis. 
In conclusion, both the detection of the VKORC1*2, *3 and *4 haplotypes 
as well as the CYP2C9*3 variant allele might be useful to select not only the most 
sensitive patients, exposed to a higher risk of over-anticoagulation, but also the 
most resistant ones, exposed to the risk of thrombosis recurrence. On August 2007, 
the USA Federal Drug Administration updated the label of warfarin to include 
information on pharmacogenetic testing and to encourage the use of this 
information in dosing individual patients initiating warfarin therapy [46]. Up to 
now, several dosing pharmacogenetic algorithms to predict a priori the maintenance 
coumarin dose [23-25, 47-53], as well as a new dose-refinement nomogram to 
guide clinicians in adjusting warfarin dose [54] have been developed. A randomized 
study of personalized, pharmacogenetic-guided warfarin dosing using both CYP2C9 
and VKORC1 variants plus clinical factors in 200 patients was recently published 
[55], showing an improvement in the accuracy and efficiency of warfarin dose 
initiation, particularly for wild-type and carriers of multiple variant genotypes. 
Despite this, a reduction in out-of –range INRs was not achieved.  
 





Pharmacogenetics results can be useful to identify patients more sensitive to 
coumarin drugs, and thus exposed to a higher risk of over-anticoagulation, as well 
as those who are more resistant to anticoagulation, and thus exposed to the risk of 
recurrence of thrombosis. The improvement and validation, by means of 
prospective clinical trials, of current pharmacogenetic-guided coumarin dosing 
algorithms, might help to predict the dose requirement of anticoagulant of coumarin 
type in order to aid clinicians to initiate therapy avoiding adverse events. This issue 
will be tackled by a prospective double-blind, randomized three-arm trial on 1.965 
participants, sponsored by the National Heart, Lung and Blood Institute and meant 
to compare three possible approaches to guiding warfarin therapy initiation: a 
strategy based on an algorithm using both clinical and genotypic information on 
genetic variants in at least CYP2C9 and VKORC1 genes, a strategy based on an 
algorithm using only clinical information and a standard, guidelinebased strategy 
[56]. 
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Background Variability in the intensity of anticoagulant therapy is considered a 
risk factor for complications, but it is unclear how best to quantify variability.  
Objective We evaluated the association of three methods to measure variability 
with complications of oral anticoagulant therapy. 
Methods We conducted a nested case-control study within a cohort of patients with 
prosthetic heart valves. 210 patients with a first haemorrhagic or thrombotic event 
during follow-up were selected with two controls per case, matched on age and 
sex. We calculated the time spent at an INR below, above and between 2.5 and 4.0; 
the variance growth rate according to three different methods (A, B1, B2), of which 
method A combines variability and time in range and methods B1 and B2 purely 
look at variability. 
Results Odds ratios of the variance growth rates for thrombotic events for patients 
in the 2nd and 3rd tertile varied between 2 and 3, with the highest odds ratio for 
complications for the method that purely looked at variability. For haemorrhagic 
complications highest odds ratios were found for measure A which also 
incorporated time in range, with ORs of 2.6 (CI95 1.3-5.1) and 3.1 (CI95 1.6-6.0) 
for the 2nd and 3rd tertile as compared to the first. The combination of time spent 
out of range with the highest tertile of variability increased the risk 2.6-fold (CI95 
1.6-4.2) as compared to subjects with stable anticoagulation within the target range.  
Conclusion Unstable anticoagulation was associated with haemorrhagic and 
thrombotic complications. Method A was best associated with complications, but 
methods B1 and B2, in combination with time spent in range were equally well 
associated. As we prefer to disentangle variability and intensity of anticoagulation, 
we propose to use methods B1 or B2 to reflect pure variability of oral anticoagulant 
therapy. 





Oral anticoagulants are among the most frequently prescribed drugs worldwide. 
They are proven to be effective in the treatment of venous thrombosis as well as for 
prevention of both venous and arterial thrombotic events in patients who are at 
increased risk[1-3]. While oral anticoagulants decrease the risk for a thrombotic 
event by inhibiting coagulation, through the same mechanism they increase the risk 
of severe or even fatal haemorrhage. Approximately 1% of patients will suffer 
from such a complication of oral anticoagulant therapy per year [4,5]. 
Given the severity of these adverse events it is of great importance to 
identify patients who are at highest risk to experience such an event so that 
precautions can be made. Several studies investigated potential risk factors for 
haemorrhagic complications, such as increased age, indication for anticoagulant 
therapy and the use of interacting medication [6-8]. Variability in the intensity of 
anticoagulant therapy (expressed as the International Normalized Ratio (INR)), as 
first described by Fihn and colleagues, is considered a risk factor for developing 
haemorrhagic or thrombotic complications [9]. They investigated whether the 
variance growth rate was associated with haemorrhagic events in a retrospective 
cohort of patients using oral anticoagulants for various indications. This variance 
growth rate is a measure of the time weighted variance of the INR around the target 
INR and reflects the degree to which a patient's achieved INR deviates from his or 
her target INR over a prolonged interval. Fihn and colleagues found that patients 
with a variance growth rate in the highest tertile had a 1.6 times higher risk of 
experiencing a haemorrhagic event compared to patients in the lowest tertile. 
Cannegieter radically modified the formula of Fihn and used the degree to which a 
patient's INR deviates from the previous one, and this variance growth rate does 
not depend on the target INR [10]. With this formula a patient is defined stable if 
his or her INRs are around the same value every time, even if this means that, for 




example, the INR is constantly above the upper limit of the therapeutic range. 
Later, Fihn described a third method to calculate the variability in INR [11]. This 
variance growth rate is approximately the same as the method of Cannegieter, with 
small differences in the denominator. Variability of the INR, calculated with any of 
these methods has been shown to be associated with an increased risk of 
developing a haemorrhagic event with odds ratios varying from 1.6 to 3.0 [9-11], 
but it is not clear which one is best associated with such events. 
Another method to assess the quality of the anticoagulant treatment is the 
linear interpolation method, which reflects the time spent within the target range, 
rather than the variability [9,12]. It has been shown that patients who spent less 
than 45% of the time inside the therapeutic range have a relative risk of 2.8 (95% 
CI 1.9-4.3) for developing an adverse event compared to patients who spent over 
65% in range [13]. 
In this study we evaluated the three variability measures to asses which one 
is most associated with the occurrence of a haemorrhagic or a thrombotic event in 
patients with mechanical heart valve prostheses. We included the time spent in 
therapeutic range in our analyses since this is the established method in literature to 
reflect the quality of oral anticoagulant therapy. 
 
Patients and Methods 
Patients were participants of the LAVA study, a large cohort study consisting of all 
patients with mechanical heart valve prosthesis treated in four regional 
anticoagulation clinics between 1985 and 1993 [14]. The main objective of this 
study in 1608 patients was to determine the optimal level of anticoagulation for this 
indication. For all patients the following data were collected: date of birth, sex, all 
INR measurements with corresponding date, all hospital admissions and deaths. 
Additional information concerning the hospital admissions were collected from 
 




hospital or general practitioners files. Outcome events were all thrombotic and 
haemorrhagic events during follow up with cerebral infarction defined as a 
neurologic deficit of sudden onset documented by CT-scanning (presence of 
infarction or absence of haemorrhage) or autopsy, peripheral emboli as acute 
peripheral ischemia proven by angiography, operation or autopsy, valve thrombosis 
defined as valve impairment by deposition of thrombus on the valve, proven at 
operation or autopsy, intracranial and spinal haemorrhage defined as neurologic 
deficit of sudden or subacute onset, confirmed by CT-scanning, surgery or autopsy, 
and major extracranial haemorrhage as an acute haemorrhagic event that led to 
death or to hospital admission for treatment of the haemorrhage as the most 
important reason for hospitalization (haemorrhage that led to hospital admission for 
diagnostic procedures only was not considered major). Out-hospital haemorrhages 
of all possible origin, i.e. also traumatic, were included. All strokes that could not 
be categorized as haemorrhagic or ischemic were designated “unclassified strokes”.  
 
We conducted a nested case-control study within the LAVA cohort. Cases were all 
patients who experienced a first thrombotic or haemorrhagic event during follow-
up. For each case two control persons were selected who were free of a 
haemorrhagic or thrombotic event at the time of the event of the case, but who 
were at risk, i.e., they were using oral anticoagulants at that date. For control 
subjects the index-date was the date of the INR measurement closest to the event 
date of the case. Control patients were matched on age and sex. A control could be 
selected more than once or become a case at a later date.  
For each patient we calculated the variability of the INR according to three 
different methods; the variance growth rate by Fihn, the variance growth rate by 
Cannegieter and the variance growth rate again by Fihn. The formulas used to 
determine these measures are shown in box 1.  
 




Box 1. Formulas of the variability measures 
  
























                                                             















   
*n is the number of INR measurements, τ is the time in weeks between the present and previous INR measurement. 
 
The variance growth rate by Fihn reflects the degree to which a patient’s 
INR deviates from his or her target INR over a prolonged period. Using this 
formula for variability, a patient is most stable when his or her INRs are close to 
the target INR. We will refer to this method as method A from now on. The 
variance growth rate by Cannegieter reflects the degree to which a patient’s INR 
deviates from the previous one. This formula is a reflection of the true variability 
not taking into account the intensity of anticoagulation. With this formula a patient 
is most stable if his or her INRs are around the same level even if this means the 
INR is constantly above the upper limit of the target range. The 2nd variance growth 
rate by Fihn is approximately the same as the formula used by Cannegieter, with 
minor differences in the denominator. Given the minor differences between the 
formula of Cannegieter and the 2nd formula of Fihn, we will refer to these methods 
as method B1 and method B2 respectively. Examples of the three measures of 
variability are given in box 2. Time in, above and below an INR range of 2.5-4.0 
was calculated using the linear interpolation method [12]. With this method the 
 




time between two measurements is divided in days and it assumes that the INR 
value between two measurements will vary linearly from the first, to the value of 
the second measurement. This way we can calculate how many days were spent at 
different INR values. Although the target range at the time of the study (1985-
1993) was an INR between 3.6 and 4.8 we considered the actual optimal INR range 
as was determined in 1996; i.e. the level at which least complications occur (INR 
between 2.5 and 4.0). 
 
Box 2. Example of three patients with target INR 3.0 and the values of three different methods to calculate the 
variance growth rate. 
 
Patient 1





























 Method A = 0.01          Method A = 1.04         Method A   = 3.23 
 Method B1= 0.01          Method B1= 4.06         Method B1 = 0.03 
 Method B2 =0.01          Method B2= 4.64         Method B2 = 0.03 
We calculated all these measures for four different time windows; one 
year, 6 months, 3 months and 6 weeks prior to the time of the event. For each time 
window only subjects were included who had INR measurements during the whole 
period of that time window. The INR measurement at the time of the event was not 
included in the calculations for the various effect measures, because this was not a 
routinely measured INR. 
 




The values of the variance growth rates and the percentage of time spent in, above 
and below INR range 2.5-4.0 were divided into tertiles (good, medium, poor) based 
on the distribution in the control persons. To asses whether being out of range 
along with a high variability is  predictive we also studied the combination of the 
time spent at INR 2.5-4.0 and the variability calculated according to method B1 
(method A includes the achieved INR and is therefore unsuitable to disentangle 
variability and time in range). For this combination we divided the time spent at 
INR 2.5-4.0 into two groups; patients in the good and medium group were 
considered to be frequently in range and patients in the poor group to be frequently 
out of range. The variance growth rate was divided into unstable (poor group) or 
stable (good and medium group). ORs were calculated for patients with high 
variability who were in INR range 2.5-4.0, patients who were stable but outside the 
range of INR 2.5-4.0 and those who were both unstable and outside INR range 2.5-
4.0, all with stable patients in the INR range as reference category. To investigate 
whether the effect is specific for the period directly preceding the event, we 
analysed the different quarters of the year prior to the event. Additional, we did 
separate analysis for phenprocoumon and acenocoumarol users. 
We performed a matched analysis calculating odds ratios (OR) and 95% 
confidence intervals (95%CI) using conditional logistic regression models. For all 
variability measures the lowest tertile is the reference category (which is the low-
risk group according to our hypothesis). For the time in therapeutic range the 
highest tertile is the low-risk group and this was chosen to be the reference 
category. We performed separate analyses for haemorrhagic events and thrombotic 
events, as well as an analysis in which the two were combined. For the subgroup 
analysis for the type of vitamin K antagonist we performed logistic regression 
analysis adjusting for the matching factors sex and age. The conditional logistic 
regression models were done with the STATA 8.0 SE software (StataCorp LP, Tx, 
 




USA), logistic regression analysis was performed with the statistical package SPSS 
version 14.0 (SPSS Inc, Chicago, Ill). 
 
Results 
Among the 1608 patients in the LAVA cohort there were 210 first events, 
consisting of 154 haemorrhagic events and 42 thrombotic events. Fourteen strokes 
could not be classified as either a haemorrhagic or an ischemic event. Thirty-three 
patients experienced an intracranial or spinal haemorrhage and 121 an extracranial 
haemorrhage. The thrombotic and embolic events were almost all cerebral 
infarctions (n=40) except for two patients who had a peripheral embolism. 
 Four hundred and twenty control subjects were matched to the 210 cases. 
One hundred and seventeen patients were selected more than once as a control, of 
whom12 patients were selected three times. Thirteen control patients became a case 
at a later date. There were slightly more women than men, 53.1% versus 46.9%. 
Median age was 66 years (IQR 58 – 72). General characteristics of cases and 
controls are shown in table 1. 
 








 Median (IQR) 66 (58-72) 66 (58-72) 
Sex   
 Male (%) 99 (46.1) 198 (46.9) 
 Female (%) 111 (53.1) 222 (53.1) 
Position of heart valve   
 Aortic (%) 111 (52.9) 233 (55.2) 
 Mitral (%) 68 (32.4) 133 (31.7) 
 Both (%) 30 (14.3) 52 (12.4) 
Coumarin   
 Phenprocoumon (%) 171 (81.1) 356 (85.2) 
 Acenocoumarol (%) 37 (17.2) 62 (14.6) 
 Other/ Unknown (%) 2 (1.0) 2 (0.2) 
 




Table 2 shows ORs for haemorrhagic events for all measures (154 cases, 
308 controls). The measures were generally most clearly predictive during the time 
window of three months, while associations became attenuated when the variance 
growth rates were calculated over longer time intervals. The risk of a haemorrhagic 
event was highest among patients who spent relatively little time within INR range 
2.5-4.0. Method A, which incorporates both time in range and variability was most 
clearly associated with the risk of haemorrhage. In the time window of three 
months we found an OR of 2.6 (95%CI 1.3-5.1) for patients in the 2nd tertile and an 
OR of 3.1 (95% CI 1.6-6.0) for patients in the highest tertile compared to patients 
in the lowest tertile. The methods that only looked at variability were associated 
with a 1.6-fold increased risk of haemorrhage in the highest tertile compared to the 
lowest for a 3-months time window. Odds ratios for all measures for thrombotic 
events are given in table 3 (42 cases and 84 matched controls). 
 
Table 2. Odds ratios for tertiles of the different measures for all haemorrhagic events 
   One year  6 Months 3  Months 6 Weeks 























 Medium 1.3 0.7-2.2 1.4 0.8-2.4 1.5 0.8-2.7 1.9 0.9-4.3 
 Poor 1.8 1.1-3.2 1.6 0.9-2.7 2.6 1.4-4.8 2.3 1.1-4.9 
          
Time above INR 4.0 Good 1.0  1.0  1.0  1.0  
 Medium 1.0 0.6-1.7 1.0 0.6-1.8 1.1 0.6-1.9 2.5 1.1-5.6 
 Poor 1.4 0.8-2.4 1.3 0.8-2.2 1.9 1.1-3.8 2.5 1.2-4.9 
          
Method A Good 1.0  1.0  1.0  1.0  
 Medium 1.2 0.7-2.1 1.9 1.1-3.4 2.6 1.3-5.1 1.8 0.9-3.7 
 Poor 1.4 0.8-2.4 1.9 1.0-3.3 3.1 1.6-6.0 1.4 0.7-2.8 
          
Method B1 Good 1.0  1.0  1.0  1.0  
 Medium 0.9 0.5-1.6 1.1 0.7-2.0 1.2 0.6-2.1 0.8 0.4-1.6 
 Poor 0.9 0.6-1.6 1.5 0.9-2.6 1.6 0.9-2.8 1.3 0.7-2.6 
          
Method B2 Good 1.0  1.0  1.0  1.0  
 Medium 1.0 0.6-1.7 1.1 0.6-1.9 1.2 0.7-2.3 0.8 0.4-1.5 








Table 3. Odds ratios for tertiles of the different measures for all thrombotic events 
       One year        6 Months 3  Months 6 Weeks 
 Tertile OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
 















 Medium 1.8 0.6-5.3 0.8 0.3-2.2 1.3 0.4-3.8 1.1 0.2-4.8 
 Poor 1.4 0.5-4.0 0.7 0.3-1.9 1.5 0.6-4.2 0.9 0.2-4.3 
          
Time below 
2.5 
Good 1.0  1.0  1.0  1.0  
 Medium 1.3 0.4-4.5 -    -  
 Poor 2.0 0.8-4.8 2.2 0.9-5.6   1.6 0.3-8.0 
          
Method A Good 1.0  1.0  1.0  1.0  
 Medium 1.5 0.6-4.0 1.3 0.5-3.6 2.1 0.7-6.1 3.2 0.6-16.9 
 Poor 1.4 0.5-4.0 1.7 0.5-5.4 1.5 0.5-4.4 1.8 0.4-8.1 
          
Method B1 Good 1.0  1.0  1.0  1.0  
 Medium 0.7 0.3-2.0 3.0 0.9-10.1 3.0 0.8-10.8 0.5 0.1-2.1 
 Poor 0.9 0.4-2.5 1.7 0.5-5.6 3.2 1.0-11.1 0.5 0.1-1.8 
          
Method B2 Good 1.0  1.0  1.0  1.0  
 Medium 0.9 0.3-2.3 2.0 0.6-6.4 2.1 0.6-6.8 0.2 0.03-0.9 




As we found in the analysis with haemorrhagic events, the measures were 
generally most clearly predictive of an event during the time window of three 
months and this risk was highest in patients who spent least time in the target zone. 
Variability method A, that combines variability and time in range showed 
increased risks with an OR of 1.5 (95% CI 0.5-4.4) for patients in the highest tertile 
compared to the lowest. The two methods that purely looked at variability now had 
higher odds ratios, of, for method B1 3.0 (95% CI 0.8-10.8) and 3.2 (95% CI 1-9.8) 
in the 2nd and highest tertile compared to the lowest tertile and 2.1 (95% CI 0.6-6.8) 
and 2.5 (95% CI 0.8-7.7) for method B2. Odds ratios for the combination of 
haemorrhagic and thrombotic events are shown in table 4. Adjustment for the value 
of the INR at the last measurement before the index date did not affect the 
outcomes, except in the analysis of thrombotic events where the ORs became more 
distinct. 




Table 4. Odds ratios for tertiles of the different measures for all adverse events 
  One year   6 Months 3  Months 6 Weeks 
Time 
window 
Tertile OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Time at 
INR 2.5-4.0 
Good 1.0 - 1.0  1.0  1.0  
Medium 1.3 0.8-2.1 1.3 0.8-2.1 1.6 1.0- 2.8 2.0 1.0- 4.0 
 Poor 1.5 1.0-2.4 1.4 0.9-2.1 2.5 1.5- 4.3 1.9 1.0- 3.8 
          
Time above 
4.0 
Good 1.0  1.0  1.0  1.0  
Medium 1.1 0.7- 1.7 1.0 0.6- 1.6 1.2 0.7-1.9 2.6 1.3-5.1 
 Poor 1.3 0.8- 2.0 1.1 0.7-1.7 1.9 1.2-3.1 1.6 0.9- 2.9 
          
Time below 
2.5 
Good 1.0  1.0  1.0  1.0  
Medium 1.2 0.7-2.2 -      
 Poor 1.6 1.1-2.4 2.0 1.3- 2.9 1.9 1.2- 3.0 1.1 0.6- 2.0 
          
Method A Good 1.0  1.0  1.0  1.0  
 Medium 1.3 0.8- 2.0 1.7 1.1-2.8 2.8 1.5– 4.9 1.6 0.9- 2.9 
 Poor 1.4 0.9- 2.2 1.8 1.1- 3.0 3.1 1.7-5.4 1.4 0.7- 2.6 
          
Method B1 Good 1.0  1.0  1.0  1.0  
 Medium 0.9 0.6- 1.5 1.3 0.8-2.0 1.4 0.8- 2.4 1.0 0.5- 1.7 
 Poor 1.0 0.6- 1.6 1.5 0.9-2.3 1.8 1.1- 3.0 1.3 0.7- 2.3 
          
Method B2 Good 1.0  1.0  1.0  1.0  
 Medium 0.9 0.6-1.5 1.2 0.7- 1.9 1.5 0.9- 2.6 1.0 0.5- 1.7 
 Poor 1.0 0.6-1.5 1.5 0.9- 2.3 1.8 1.1- 2.9 1.1 0.6- 2.0 
 
 
Subsequently, we combined the pure variability methods (B1 and B2) with 
the time spent in and outside the INR target range of 2.5 and 4.0. The risk of a 
haemorrhagic or thrombotic event was increased 2.6-fold (95%CI 1.6-4.2) for 
those in the highest tertile of variability and lowest time-in-range tertile as 
compared to subjects with stable anticoagulation who were usually within the 
target range (table 5). Variability within an INR range of 2.5 – 4.0 did not affect 
risk. Again, the effect was only seen in the three months directly preceding the 
event. In a subgroup analysis of phenprocoumon and acenocoumarol users we 
found similar results for all measures, but the associations were more pronounced 
in acenocoumarol users. 
 
 























In range Stable 1.0 - 1.0 - 1.0 - 
 Unstable 1.0 0.5-2.0 1.1 0.4-3.5 1.2 0.7-2.1 
Outrange Stable 1.6 0.9-3.1 0.8 0.3-2.6 1.5 0.9-2.6 
 Unstable 2.7 1.4 - 4.9 2.5 0.8-7.9 2.6 1.6-4.2 
*In range are patients with a time in therapeutic range in the 2nd and highest tertile, outrange are patients in the lowest tertile. 
** Stable are patients who have a variance growth rate calculated with method B1 in the lowest or 2nd tertile, unstable are patients 
in the highest tertile. 
 
Discussion 
In this study of 630 subjects with mechanical heart valve prostheses we found that 
unstable anticoagulation was associated with an increased risk of haemorrhagic and 
thrombotic complications. Both variability and time spent outside the target range 
affected risk. The variance growth rate described by Fihn, method A, incorporates 
both aspects of instability, and was therefore most clearly associated with 
complications of anticoagulant therapy, especially haemorrhagic episodes. 
Thrombotic events were most clearly predicted with variability calculated with 
method B1 and B2, which only concern variability of the INR and not the time 
within range. The optimal time window to determine these measures was three 
months. 
Periods of time outside the therapeutic range are intrinsically related to the 
treatment and therefore not avoidable. The problem is to have an instrument to 
quantify them to obtain a better quality of anticoagulation in order to reduce 
adverse events. Several studies have been done to investigate potential instruments 
to quantify this quality, and research concerning this topic is ongoing. Our study 




showed similar results as the previous studies have shown [9-11,13]. From these 
studies we knew that the measures we evaluated could predict which patients were 
at increased risk, but we did not know which one was best associated since they 
have never been compared directly to each other. In another study it was shown 
that patients with episodic overanticoagulation had an increased risk of both 
haemorrhagic and thrombotic events [15]. The authors suggest that this 
phenomenon reflects instability of anticoagulation. These results are in line with 
our findings, since the variability measures increase when patients have episodes of 
high INR levels. 
Overall, the variability according to method A was best associated with 
complications of oral anticoagulant therapy. However, this method is a composite 
of time in range and variability.  When we combined the methods that only looked 
at variability with a measure of time in range, this predicted equally well. The 
importance of the association of risk of the methods that only look at the variability 
of the INR, is that we show this is a risk factor per se, added to the risk of under- 
and overanticoagulation. When we adjusted for the value of the last INR before the 
index date the effect did not disappear, which teaches us that an INR within the 
therapeutic range in patients with high variability in INRs can not be interpreted 
the same way as in patients who are very constant in their INRs. Remarkably, the 
achieved intensity of anticoagulation was less important in predicting thrombotic 
events than haemorrhagic events. 
The lack of association in the time windows of one year and six months 
may be the result of the dilution of the effect of the variability measures when 
calculated over a prolonged period. This is also supported by the results of our 
analysis of quarters of the year prior to an event, where we only found an 
association in the three months directly preceding the event. Remarkably, a six 
weeks time window had little association. This may be the result of the limited 
 




number of INRs which are available in such a period. Time between two visits can 
be as long as six weeks, so in a time window of 6 weeks prior to the event, few 
patients will have sufficient INR measurements to reliably calculate the various 
measures. Consequently, three months is the optimal time window to predict 
thrombotic and haemorrhagic risk by variability. 
We have shown that unstable anticoagulation is associated with 
haemorrhagic and thrombotic complications. The variance growth rate calculated 
by method A is best associated with complications. However, this method does not 
inform us on the reason for the increased risk. Since methods B1 and B2 in 
combination with the time spent at INR 2.5- 4.0 are equally well associated, we 
prefer to disentangle variability in and intensity of anticoagulation. Disentangling 
the variability and the time in therapeutic range gives us the opportunity to target 
more directly either the instability or the inadequate level, hence possibly 
preventing these events. Therefore we propose to use the variance growth rates by 
Cannegieter or Fihn, methods B1 and B2 to reflect the variability of oral 
anticoagulant therapy. 
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Background: Patients who are unstably anticoagulated or who spent much time 
outside their therapeutic range are at an increased risk for complications. Factors 
associated with unstable anticoagulation are not well known. 
Objectives: To investigate the association of patient characteristics, lifestyle factors 
and treatment-related factors with unstable anticoagulation. 
Patients and Methods: Patients were participants in a randomized controlled trial 
with the main objective to compare two different algorithms for computer-assisted 
dosing of oral anticoagulants. All patients completed a questionnaire concerning 
lifestyle factors. 
Results: 638 patients (response 91.3%) returned the questionnaire. Unstable 
anticoagulation was observed more frequently with the use of acenocoumarol 
versus phenprocoumon (RR 2.3, 95%CI 1.9-2.8), in individuals with daily 
strenuous physical activity (RR 1.4, 95%CI 0.7-2.7) and less frequently in obese 
patients (RR 0.7, 95%CI 0.5-1.0). Patients who were underweight (RR 1.5, 95%CI 
0.2-12.8), obese (RR 1.8, 95%CI 0.7-4.4), or had daily strenuous physical activity 
(RR 4.1, 95%CI 0.8-22.1) had an increased risk of spending more than 50% out of 
range, while regular alcohol use (>1-2-times a week) decreased the risk with 30-
50%. Furthermore, patients with high daily anticoagulant dosages were less likely 
to spend more than 50% out of range than those with low doses. 
Conclusion: Unstable anticoagulation is associated with the use of acenocoumarol 
versus phenprocoumon and strenuous daily physical activity. Obesity decreases the 
risk for instability. Low anticoagulant dosages, strenuous daily physical activity, 
being underweight or obese and frequent alcohol use are associated with an 
increased risk of spending less than 50% in the therapeutic range.





Vitamin K antagonists are among the most frequently prescribed drugs worldwide. 
They are proven to be effective in the treatment and prophylaxis of venous and 
arterial thrombosis [1-3]. At the same time, vitamin K antagonists are also listed in 
the top 5 of drugs causing adverse events [4]. In routine clinical practice, vitamin K 
antagonists result in severe bleeding complications in 1-2% of patients [5-7]. 
Vitamin K antagonists have a narrow therapeutic window, and frequent 
monitoring of the anticoagulant effect by measurements of the International 
Normalised Ratio (INR) with adjustment of anticoagulant dose is required to 
maintain patients within the therapeutic range. Patients who are insufficiently 
anticoagulated (i.e., an INR below the therapeutic window appropriate for their 
indication) are at increased risk for (re)thrombosis, whereas over-anticoagulated 
patients show a sharp increase in bleeding risk [8]. Keeping patients’ INR within 
the therapeutic window is difficult due to the large variability in the dose needed to 
achieve the optimal anticoagulant effect within a single patient. Sensitivity for 
vitamin K antagonists not only differs between patients, but also within patients it 
may vary over time [9]. The risk for bleeding or thrombosis proportionally 
increases with the time spent outside the therapeutic window [8]. Bleeding or 
thrombosis risk is also increased in patients who are unstably anticoagulated, 
independently from the achieved time within the therapeutic window [10-12]. 
Thus, low-risk anticoagulation not only requires the patient to be within its 
therapeutic window for the majority of time, but also requires deviations in INR 
over time to be small. 
In a case-control study, unstable anticoagulation has been shown to have 
many determinants [13]. Patients who had an INR above 4.5, workers versus 
pensioners, users of acenocoumarol versus warfarin and patients who had a poor 
compliance were considered often unstable. Instability in this study was defined 




according to the opinion of experts in anticoagulant dosing, because there was a 
lack of universally accepted criteria for instability. Recently, it has been shown that 
stability of anticoagulation can be objectively measured by calculating the variance 
growth rate. This variance growth rate reflects the degree to which a patient’s INR 
deviates from the previous one and is independent from a patient’s target INR. 
Instability defined by this variance growth rate was shown to be associated with an 
increased risk for bleeding or thrombotic events [10].  
In this study our aim was to identify factors that are associated with 
unstable anticoagulation using the variance growth rate to calculate stability. In 




Patients were participants in a randomized controlled double-blind trial conducted 
at the Leiden Anticoagulation Clinic in the Netherlands. Main objective of the trial 
was to evaluate two algorithms (TRODIS and ICAD) for computer-assisted dosing 
in clinical practice. In total 712 patients participated in the trial. Enrollment 
occurred between August 14th and October 16th 2003. Patients were eligible when 
they had an indication for long-term anticoagulant therapy and were between the 
ages of 18 and 80 years. Patients were excluded when they were participating in 
the patient self-management program, stayed long periods abroad or were in a 
terminal stage of disease. Randomization was done stratified by the indication for 
oral anticoagulant treatment, age and sex using the minimization method [14]. The 
study was double- blind, e.g., neither patients nor physicians were aware which 
group the patient was randomized to. Follow-up was until September 1st 2004, i.e. 
maximally about one year. All patients filled in a questionnaire at the start of the 
study containing questions about the attitude towards their anticoagulant treatment 




and lifestyle factors such as smoking habits, alcohol use, vitamin intake and 
sporting activities. The study was approved by the Medical Ethics Committee of 
the Leiden University Medical Center before start of the study and each patient 
gave written informed consent before randomization. The trial is registered in the 
ISRCTN trial registration with identifier ISRCTN27801917. The trial is described 
in more detail elsewhere [15]. 
 
Because of our previous finding that the time spent within the therapeutic range 
was similar for both algorithms [15], and instability was similar (median 0.22, 
interquartile range (IQR) 0.09-0.57 vs. median 0.26, IQR 0.12-0.61, p=0.064) we 
pooled data of the two groups and considered it as a cohort. We performed 
analyses for two outcome events. The first outcome event was unstable 
anticoagulation. Unstable anticoagulation was calculated with the following 
formula for the variance growth rate:  
 












In this formula n is the number of INR measurements and τ the time between two 
visits in weeks. The variance growth rate is a reflection of the amount of deviation 
of a patient’s INR from the previous INR. The σ will be high in patients with 
highly varying INR values and low if the INR is consequently at the same value 
every time, even if this means the INR is constantly outside the therapeutic range. 
The stability was calculated over the first 6 months of follow up. The values of the 
variance growth rates were divided into tertiles (good, medium, poor), and patients 
in the third tertile were considered unstably anticoagulated.  




In the second analysis we analyzed the time spent outside the therapeutic 
range. The time in therapeutic range was calculated over the first 6 months after 
start of the study with the linear interpolation method [16]. We considered patients 
who spent more than 50% outside their therapeutic range to have experienced the 
outcome event. Therapeutic ranges were as they were applied in our routine 
anticoagulant practice: INR 2.0 to 3.5 for low intensity and INR 2.5 to 4.0 for 
indications requiring a higher intensity. Patients who had less than 3 INR 
measurements were excluded from the analyses. 
 
We investigated the association of sex, smoking, alcohol use, vitamin use, the use 
of a specific diet (e.g. low carb, low salt), daily physical activity, sporting 
activities, BMI, type of vitamin K antagonist and dosage with unstable 
anticoagulation and time outside range. We developed a questionnaire to measure 
all factors, except for the type of vitamin K antagonist and dosage used which were 
derived from the database at the anticoagulation clinic. Smoking was divided in 
three categories: smokers, former smokers and non-smokers. Former smokers were 
considered non-smokers if they had quit smoking more than half a year before 
inclusion in the study. Alcohol use was categorized according to the amount of 
consumption. Daily physical activity refers to the amount of activity due to work, 
whereas sporting activities only includes physical activity due to sports. The degree 
of daily physical activity was categorized by patients themselves as light, 
moderate, heavy or strenuous. Patients were divided into four categories for Body 
Mass Index (BMI): underweight (BMI <20), normal weight (BMI 20-25), 
overweight (BMI 25-30) and obese (BMI>30). The mean daily dosages of vitamin 
K antagonist were divided into quartiles for phenprocoumon and acenocoumarol 
separately.  
 





We calculated relative risks (RR) for either unstable anticoagulation (variance 
growth in third tertile) or time outside of range (more than 50% outside range). We 
report RRs with their corresponding 95% confidence intervals (95% CI). 
Continuous variables are presented as the median with interquartile range (IQR). 
All calculations were performed using the statistical package SPSS version 14.0 
(SPSS Inc, Chicago, Ill, USA). 
 
Results 
Of the 712 patients included in the trial, thirteen patients discontinued treatment 
before there were 3 INR measurements available. The reasons for discontinuation 
were: the treatment ended (n=3), participation in the patient self management 
program (n=6), death (n=2) or other reasons (n=2). Of the 699 patients, 638 
(91.3%) filled in the questionnaire and were included in the current analysis. The 
median age of the participants was 68 years (Interquartile range (IQR) 59-74) and 
there were slightly more men than women (67.2%). Most patients used 
phenprocoumon at a low intensity.  
Table 1. Patient characteristics (n=638) 
   
 
Age  
 Median (IQR) 68.0 (59-74) 
Sex  
 Men (%) 67.2 
Indication  
 Atrial Fibrillation (%) 43.7 
 Venous thrombosis (%) 12.4 
 Heart valve prosthesis (%) 10.3 
 Other cardiac indication (%) 18.2 
 Peripheral vascular disorder (%) 9.5 
 Cerebrovascular (%) 6.0 
Coumarin  
 Acenocoumarol (%) 14.3 
 Phenprocoumon (%) 85.7 
Intensity (target)  
 Low (2.0 – 3.5) (%) 62.2 
 High (2.5 – 4.0) (%) 35.3 
 Switched (%) 2.5 





The main characteristics of the patients are shown in table 1. The patients who did 
not fill in the questionnaire were not different with respect to age and sex compared 
to those who filled in the questionnaire. The median value for the instability 
calculated with variance growth rate was 0.25 (IQR 0.10-0.58). The median time 
spent in therapeutic range was 82.5% (IQR 69.9 – 94.9). The mean daily dosage of 
phenprocoumon was 2.27 mg (IQR 1.59-2.72) with a maximum of 9.96 mg. For 
acenocoumarol users the mean daily dosage was 2.53 mg (IQR 1.67-3.17) with a 
maximum daily dosage of 6.12 mg. 
 
Determinants of unstable anticoagulation 
The 67th percentile of the variance growth rate was 0.45 and patients with a 
variance growth rate ≥ 0.45 were considered unstably anticoagulated. We 
investigated the association of the patient characteristics and lifestyle factors sex, 
BMI, smoking status, daily physical activity, work, sporting activities, alcohol use, 
vitamin use, the use of a specific diet with unstable anticoagulation (table 2).  
Obese patients had a 30% lower risk of unstable anticoagulation than 
patients with normal weight (RR 0.7, 95% CI 0.5-1.0). Smoking was not associated 
with unstable anticoagulation. Strenuous physical activity showed a small 
increased risk for unstable anticoagulation (RR: 1.4, 95% CI 0.7-2.7) compared to 
patients who had light physical activity. Patients who did not work had a 1.2 times 
increased risk compared to patients who worked (95% CI 0.9-1.5). We did not 
observe an association with unstable anticoagulation and sex, vitamin use, sporting 
activities, the use of a specific diet, or alcohol use. 




Table 2. Relative risks for the association between patient characteristics and lifestyle factors and unstable 
anticoagulation and time out of range. 
 Unstable anticoagulation Time out of range 
  RR 95%CI RR 95% CI 
Sex     
 Male 1.0 (ref) - 1.0 (ref)  
 Female 0.9 0.7-1.2 1.1 0.5-2.1 
BMI     
 Underweight 0.9 0.4-1.9 1.5 0.2-12.8 
 Normal weight 1.0 (ref) - 1.0 (ref) - 
 Overweight 0.9 0.5-1.6 1.1 0.5-2.6 
 Obese 0.7 0.5-1.0 1.8 0.7-4.4 
Smoking     
 No 1.0 - 1.0 - 
 Former 0.9 0.7-1.2 0.6 0.3-1.3 
 Yes 1.0 0.7-1.4 0.6 0.2-1.7 
Daily physical activity     
 Light 1,0 (ref)  1,0 (ref)  
 Moderate 0.7 0.5-1.1 0.9 0.3-2.9 
 Heavy 1.0 0.6-1.7 0.6 0.1-5.0 
 Strenuous 1.4 0.7-2.7 4.1 0.8-22.1 
Work     
 Workers 1.0 (ref)  1.0 (ref)  
 Non workers 1.2 0.9-1.5 1.3 0.7-2.7 
Sporting activities     
 Yes 1.0 (ref)  1.0 (ref)  
 No 1.1 0.9-1.4 1.0 0.5-1.9 
Alcohol use     
 Never 1.0 (ref)  1.0 (ref)  
 < 1 x per mnd 0.9 0.2-5.0 1.9 0.5-6.3 
 < 1 x per week 1.1 0.7-1.6 1.7 0.6-4.7 
 1-2 days per week 0.9 0.6-1.3 0.7 0.2-2.3 
 3-4 days per week 0.8 0.5-1.3 0.5 0.1-2.6 
 5-7 days per week 1.1 0.8-1.5 0.7 0.2-1.7 
Vitamin use     
 No 1.0 (ref)  1.0 (ref)  
 Yes 0.9 0.7-1.2 0.9 0.4-1.9 
Specific diet     
 No 1.0 (ref)  1.0 (ref)  
 Yes 1.2 0.9-1.6 0.6 0.3-1.4 
 
 
In table 3 RRs are shown of the association between treatment related 
factors, type of vitamin K antagonist, target INR range, mean daily dosage and 
unstable anticoagulation. Users of acenocoumarol had a 2.3 fold increased risk for 
unstable anticoagulation, i.e. a high variance growth rate (95% CI 1.9-2.8). Patients 
with a high therapeutic range had a slightly increased risk of unstable 
anticoagulation with a RR of 1.4 (95% CI 1.1-1.7) compared to patients with a low 




therapeutic range. Higher anticoagulant dosage tended to give a slightly decreased 
risk, with relative risks for the 2nd and 3rd quartile of 0.8 (95% CI 0.6-1.1), but this 
was not seen for patients with the highest dosages (RR 0.9, 95% CI 0.7-1.2). The 
association between the mean daily dosage and instability was similar for 
acenocoumarol users and phenprocoumon users.  
 
Table 3. Relative risks for the association between several treatment related factors and unstable anticoagulation 
and time out of range. 
 Unstable anticoagulation Time out of range 
  RR 95%CI RR 95% CI 
Vitamin K antagonist     
 Phenprocoumon 1.0 (ref) - 1.0 (ref) - 
 Acenocoumarol 2.3 1.9-2.8 0.7 0.2-2.0 
Target zone     
 Low (2.0-3.5) 1.0 (ref)  1.0 (ref)  
 High (2.5-4.0) 1.4 1.1-1.7 1.0 0.5-2.0 
 Switched 2.3 1.1-3.0 2.3 0.5-10.8 
Dosage     
 Lowest quartile 1.0 (ref)  1.0 (ref)  
 Second quartile 0.8 0.6-1.1 0.3 0.1-0.7 
 Third quartile 0.8 0.6-1.1 0.4 0.2-1.0 
 Highest quartile 0.9 0.7-1.2 0.2 0.1-0.6 
 
 
Determinants for time spent outside the therapeutic range 
Thirty eight (6.0%) patients spent more than 50% of the time outside the 
therapeutic range. Patients being underweight or obese patients tended to be at 
increased risk for spending 50% or more outside the therapeutic range with RRs of 
1.5 (95% CI 0.2-12.8) and 1.8 (95% CI 0.7-4.4) compared to patients with normal 
weight, although their confidence intervals contained 1.0. Former smokers 
(smoking terminated less than half a year before inclusion into the study) and 
smokers had a 40% lower risk compared to patients who did not smoke or stopped 
smoking more than half a year before inclusion. Patient regularly using alcohol 
(more than 1-2 time a week) had a 30-50% decreased risk to be out of range 
compared to patients who never use alcohol. We did not observe an association 




between time out of range and sex, the use of vitamin supplements and sporting 
activities. 
In contrast to the results for unstable anticoagulation there was a decreased 
risk for acenocoumarol users to be out of range compared to phenprocoumon users 
(RR 0.7, 95% CI 0.2-2.0) (table 3). There was a strong association between the 
anticoagulant dosage and spending more than 50% out of range. Patients in the 
highest quartile of the anticoagulant dosage had an 80% reduced risk compared to 
patients in the lowest quartile (RR: 0.20, 95% CI 0.1-0.6).  
 
Discussion 
In this study we have shown that unstable anticoagulation is observed more 
frequently with the use of acenocoumarol versus phenprocoumon, in individuals 
with daily strenuous physical activity and less frequent in obese patients. Patients 
who are obese, have daily strenuous physical activity or are frequent alcohol users 
have a higher risk of spending more time outside the therapeutic range. 
Furthermore, increased anticoagulant dosage substantially reduced the risk of time 
spent outside range.  
Our study showed similar results as the study of Palareti et al. [13]. They 
showed that users of the short acting acenocoumarol had an increased risk for 
unstable anticoagulation compared to users of the longer acting warfarin. We found 
that also compared to the longest acting vitamin K antagonist phenprocoumon, 
acenocoumarol users were at an increased risk for instability. It is remarkable that 
the use of acenocoumarol was associated with unstable anticoagulation but not 
with spending 50% or more time outside the therapeutic range. Overall, 
acenocoumarol users did have a lower mean time spent within range, but the 
proportion of patients with a time outside the therapeutic range of more than 50% 
was smaller compared to phenprocoumon. We can explain this by the fact that 




phenprocoumon users have a wider range in time in therapeutic range compared to 
acenocoumarol users with a large amount of patients spending more than 80% of 
time within the therapeutic range. This leads to an overall better quality of 
treatment for phenprocoumon compared to acenocoumarol, although the number of 
patients who spent less than 50% in range is larger. Instability is associated with 
the time spent in range, but the association is stronger with higher time in range. 
Several studies have shown that vitamin K antagonists with a shorter half-life are 
associated with poorer quality (less time within the therapeutic range) of 
anticoagulant treatment, although some studies did not confirm these findings [17-
19]. Our study indicates that this poorer quality might be caused by an increased 
instability rather than spending more time out of range. 
Patients requiring higher anticoagulant dosages had a decreased risk for 
spending more than 50% of the time outside the therapeutic range. Patients who 
require low anticoagulant dosages may be more sensitive to small changes in the 
dosage, since these dose changes are relatively larger for small dosages than for 
high dosages. In earlier studies it has been shown that carriers of the CYP2C9 
polymorphisms CYP2C9*2 and CYP2C9*3 need lower anticoagulant dosages and 
have a higher risk for adverse events [20-22]. Also the VKORC1 haplotype has 
been shown to be of influence on the anticoagulant dosages. The decreased risk for 
spending more time out of range we found for patients with high anticoagulant 
dosages might be explained by CYP2C9 genotype and VKORC1 haplotype. 
Unfortunately we could not investigate this in our study since DNA samples were 
not available. 
Of the lifestyle factors we investigated, only daily physical activity was 
positively associated with unstable anticoagulation and spending more than 50% of 
the time out of range. In contrast to the results of the study by Palareti et al. we 
observed only a small increased risk for patients who did not work compared to 




workers. Obesity was shown to decrease the risk for unstable anticoagulation and 
increase the risk for spending more than 50% outside the therapeutic range. This 
contradictive finding was caused by several obese patients who were stably 
anticoagulated with INR values around the upper or lower values of the therapeutic 
range.  
We used a questionnaire to obtain information about lifestyle factors so it 
is possible that patients filled in favourable answers for these factors since it is well 
known that some lifestyle factors such as smoking and drinking large amounts of 
alcohol have negative effects on health. If this is true we would have found risks 
that are underestimated.  
In conclusion, unstable anticoagulation defined by the variance growth rate 
occurs more frequently with the use of acenocoumarol versus phenprocoumon, in 
patients with strenuous daily physical activity and is reduced in obese patients. 
Spending more than 50% outside the therapeutic range was associated with obesity, 
strenuous daily physical activity, frequent alcohol use and lower anticoagulant 
dosages. 
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Context  Several studies have compared different vitamin K antagonists with 
regard to the quality of treatment, e.g. stability. The results were mostly, but not 
always, in favour of the longer acting vitamin K antagonists. Only one randomised 
study compared warfarin and phenprocoumon. 
Objective The aim of our study was to investigate whether oral anticoagulant 
treatment with warfarin leads to a more or less stable anticoagulant status than is 
achieved with phenprocoumon. 
Methods We conducted a randomised controlled trial among patients with an 
indication for anticoagulant treatment at the Leiden Anticoagulation Clinic. We 
included patients who initiated oral anticoagulant therapy and patients who were 
already using a different vitamin K antagonist (acenocoumarol), and who were 
switched. We compared an oral anticoagulant treatment with warfarin with a 
treatment with phenprocoumon. Follow-up was 6 months. The primary outcome 
measure was the percentage of time spent in therapeutic range. 
Results From March 1st 2004 to January 2008, 312 patients finished the follow 
period and were included in this analysis. One patient died before the first INR 
measurement. The median time spent in the therapeutic range was 74.7% (IQR 
58.8-87.0). Thirty eight percent of patients spent more than 80% of the time in 
therapeutic range. There was no difference in time spent in the therapeutic range 
between men and women, and between patients who initiated oral anticoagulant 
treatment and patients who switched from acenocoumarol. The median time 
between two visits was 11.7 days (IQR 10.0 – 13.9). 
Trial registration The trial is registered in the ISRCTN register with identifier 
ISRCTN60446748. (www.controlled-trial.org) 





Coumarins are among the most frequently used drugs worldwide and the number of 
indications for which they are prescribed is still growing. Worldwide there are 
different vitamin K antagonists available. There are three different types most 
frequently used: acenocoumarol, warfarin and phenprocoumon. These vitamin K 
antagonists mainly differ in half-life: Acenocoumarol has the shortest half-life of 
11 hours, followed by warfarin with 36-42 hours and the longest half-life is seen in 
phenprocoumon with approximately 140 hours [1-4]. The clearance of these 
coumarins also is dissimilar. Acenocoumarol is for its elimination completely 
dependent on hydroxylation by cytochrome p450 (CYP). Warfarin is also 
dependent on reduction processes [5]. Phenprocoumon can, in addition to 
elimination as hydroxylated metabolites, be eliminated as parent compound and is 
thus less dependent on hydroxylation by CYP. These differences in dependence on 
hydroxylation by the CYP enzymes offer an explanation of different responses 
found in studies investigating the effects of polymorphisms in the CYP2C9 gene on 
clearance of specific coumarin classes [6,7]. Several studies have compared these 
different vitamin K antagonists with regard to the quality of treatment, e.g. 
stability. Most studies have compared the short acting acenocoumarol to the longer 
acting warfarin or phenprocoumon. The results were mostly, but not always, in 
favour of the longer acting vitamin K antagonists. [8-16]. Only one randomised 
comparison between warfarin and phenprocoumon was made by Rodman et al. in 
1964 [15]. In their comparative study they evaluated 4 different anticoagulants: 
phenprocoumon, bishydroxycoumarin, diphenadione and warfarin. They concluded 
that phenprocoumon appeared to be superior to the other anticoagulants in terms of 
ease of maintenance therapy, although all others were also  satisfactory for clinical 
use.  




The aim of our study was to investigate whether oral anticoagulant 
treatment with warfarin leads to a more stable oral anticoagulant treatment than is 
achieved with phenprocoumon. In this report we will discuss the design of the 
study and give general results regarding the quality of oral anticoagulant treatment 




We performed a randomised controlled trial comparing two groups: patients 
receiving oral anticoagulant treatment with phenprocoumon and patients using 
warfarin. We used block randomisation stratified for the centre a patient was 
referred from to assure an equal number of patients on both anticoagulants among 
patients from each centre. The study was not blinded since dosing of warfarin and 
phenprocoumon has to be done in different ways due to the difference in half life. 
For safety reasons, it is also necessary that patients and physicians are aware of 
which vitamin K antagonists they are taking. 
The study was conducted at the Leiden Anticoagulation Clinic in the 
Netherlands. At this anticoagulation clinic most patients are treated with 
phenprocoumon (approximately 80%), all other patients are treated with 
acenocoumarol. Warfarin is not registered for use in the Netherlands.  
 
Patients 
Recruitment of patients occurred from March 1st 2004 and is ongoing. Two patient 
groups were included in the trial. The first group consisted of patients initiating 
oral anticoagulant treatment and was recruited from three hospitals, all in the 
greater Leiden area, i.e., the departments of Cardiology and Internal Medicine of 
the Leiden University Medical Center, Diaconessenhuis Leiden, and Rijnland 




Hospital Leiderdorp and at the department of Orthopedics of the Leiden University 
Medical Center. Patients were eligible to participate when they were aged between 
18 and 85 years and had an indication for anticoagulant treatment which required 
treatment for at least three months. Exclusion criteria were pregnancy or intended 
pregnancy, renal dialysis, chemotherapy, known allergic reactions to warfarin or 
phenprocoumon or a contra-indication to oral anticoagulant treatment. Only 
patients who lived in the working area of the Leiden Anticoagulation clinic could 
participate in the study. Patients were randomised to a treatment with either 
phenprocoumon or warfarin and were followed until end of treatment or, when the 
indication required the treatment to continue over 6 months, follow-up ended at 6 
months. 
The second group included in this trial consisted of patients already using 
acenocoumarol and who were recruited at the Anticoagulation clinics of Leiden 
and The Hague. We chose patients using acenocoumarol so that for the study 
participants always had to switch to a treatment with another vitamin K antagonist, 
and there was no possibility of attrition of susceptibles specific to phenprocoumon.  
Patients were eligible to participate when they were aged between 18 and 85 years 
and had an indication for long term anticoagulant treatment. For this group the 
same exclusion criteria were applied as was for the first group. After written 
informed consent they were randomized and switched to a treatment with either 
phenprocoumon or warfarin and follow-up was again 6 months.  
All patients participating in the trial were part of the routine care in the 
Anticoagulation clinic. We obtained approval from Medical Ethics Review 
Committee of the Leiden University Medical Center before start of the study and 
all patients gave written informed consent before randomization. The trial is 
registered in the ISRCTN register with identifier ISRCTN60446748 
(http://www.controlled-trials.com). 






We analysed all patients treated at the Leiden Anticoagulation clinic who finished 
the follow-up period at January 1st 2008. The primary outcome measure was 
quality of anticoagulant therapy, which was defined as the mean percentage of time 
spent in the therapeutic range. We used the linear interpolation method to 
determine this quantitative measure of quality of anticoagulant therapy [17]. 
Therapeutic ranges were as they were applied in our routine anticoagulant practice: 
an INR between 2.0 and 3.5 for most indications (i.e. venous thrombosis, atrial 
fibrillation) and between 2.5 and 4.0 for patients needing a high intensity of 
anticoagulation (e.g. patients with prosthetic heart valves). In case a patient had 
less than 2 INR measurements in total, no time in therapeutic range was calculated, 
and the patient was excluded. When the time between two INR measurements 
exceeded 9 weeks, no time in therapeutic range was calculated for this period, and 
this period was excluded. 
Secondary outcome measures were the median time between visits, the 
time above and below the therapeutic range and the time needed to achieve an INR 
within range after start of treatment. Bleeding complications were classified as 
major when they were fatal or necessitated hospitalisation. Minor bleeding 
complications were all other bleeding events, in which ecchymoses were only 
counted when more than 10 cm in diameter and epistaxis only when the duration 
exceeded 30 minutes. 
 
Statistical Analyses 
All outcomes are shown as means or percentages with the corresponding 95% 
confidence interval of the difference based on t or binomial distributions or 




medians with the corresponding interquartile range (IQR). All calculations were 
performed using the statistical package SPSS version 14.0 (SPSS Inc, Chicago, Ill). 
 
Results 
From March 1st 2004 to January 2008, 405 patients were included of whom 312 
patients finished the study. One patient dropped out, while 75 had not completed 
the 6 months study duration. Of the 312 patients, 162 were randomised to the 
warfarin group and 150 to the phenprocoumon group. The study population 
consisted of 218 patients who initiated an oral anticoagulant therapy (112 warfarin 
group, 106 phenprocoumon group) and 94 patients who were already treated with 




Figure 1. Enrollment, Randomisation and Data Analysis 





One patient discontinued the treatment before the first INR measurement 
because of a bleeding complication (phenprocoumon group). The total follow up 
time was 119.3 person years, 63.2 person years in the warfarin group and 56.1 
person years in the phenprocoumon group. Seventy five patients had a follow up 
shorter than 6 months for various reasons. Two patients stopped the treatment 
because of treatment-related complications (1 warfarin group, 1 phenprocoumon 
group) and 1 patient died of unknown cause (phenprocoumon group). Figure 1 
summarises enrolment, randomisation, follow up and analysis of all patients.  
Baseline characteristics are shown in table 1. There were more men than 
women (201 (62.2%) women versus 111 men (34.4%)), equally divided over the 
two treatment groups. Median age was 66 years (IQR 58-73). The majority of 
patients started with oral anticoagulants because of atrial fibrillation or venous 
thrombosis. Almost all patients had a target intensity of INR 2.5 – 3.5. 
Demographic characteristics, indication for oral anticoagulant treatment, and target 
intensity of anticoagulation did not differ between the two groups. 
 
Table 1. Patient characteristics 
  Patients treated with 
warfarin 
(n=162) 
Patients treated with 
phenprocoumon 
(n=149) 
Age   
 Mean (IQR) 64.1 (59-73) 63.3 (56-74) 
Sex   
 Men (n, %) 110 (67.9) 91 (61.1) 
Indication   
 Atrial Fibrillation (n, %) 79 (48.8) 70 (47.0) 
 Venous thrombosis (n, %) 31 (19.1) 25 (16.8) 
 Heart valve prosthesis (n ,%) 9 (5.6) 9 (6.0) 
 Other cardiac indication (n ,%) 9 (5.6) 9 (6.0) 
 Prophylactic (n, %) 32 (19.8) 32 (21.5) 
 other (n, %) 2 (1.2) 4 (2.7) 
Intensity (target)   
 Low (2.5 – 3.5) (n, %) 144 (88.9) 129 (86.6)  
 High (3.0 – 4.0) (n, %) 15 (9.3) 20 (13.4) 
 Switched (n, %)  3 (1.8) 0 (0.0) 
Group   
 Initiating oral anticoagulant treatment 112 (69.1) 105 (70.5) 
 Switched from acenocoumarol 50 (30.9) 44 (29.5) 






The median time spent within the therapeutic range was 74.7% (interquartile range 
(IQR) 58.8-87.0). Patients who switched from acenocoumarol to warfarin or 
phenprocoumon spent an equal amount of time in the therapeutic range as patients 
initiating treatment (75.8% versus 73.4%). There was no difference in time in 
therapeutic range between men and women (74.5% versus 75.1%). One hundred 
and nineteen patients (38.1%) spent more than 80% of the time within their 
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Figure 2. Percentage of time spent within therapeutic range. 
 
 
Time between two visits is shown in figure 3. Overall, the median time between 
two visits was 11.7 days (IQR 10.0 – 13.9), with 59.2% of patients with a median 
time between two visits between 10 and 15 days. 
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Figure 3. Median time between two visits 
 
Discussion 
In this study we described the study design of our trial of which the primary aim is 
to compare the quality of a treatment with warfarin to the quality of a treatment 
with phenprocoumon. In addition we gave an overview of the overall quality of 
anticoagulant treatment, without giving the results for the two treatment groups 
separately since the trial is ongoing. The overall quality of anticoagulant treatment 
was high, with a median time spent within the therapeutic range of 74.7% (IQR 
58.8-87.0). 
This study has several potential limitations.  Firstly, in our anticoagulation 
clinic the majority of patients is treated with phenprocoumon. This may potentially 
bias the present comparison between anticoagulant treatment with phenprocoumon 
versus warfarin, since the physicians dosing the patients are experienced in dosing 
phenprocoumon, but inexperienced in dosing warfarin. We will investigate this 
phenomenon with an analysis in which we compare patients randomised to a 




treatment with warfarin in the beginning of the trial to patients randomised to 
warfarin at the end of the trial to see whether there was a large learning effect in 
warfarin dosing among the physicians. 
Secondly, this study was not blinded. Blinding of trials was introduced to 
ensure random allocation, to avoid selective drop-outs, to avoid differential co-
treatment, and to avoid bias in the assessment of the outcome measures. It is 
believed that randomised controlled trials are optimally valid when patients as well 
as physicians or investigators are blinded for which treatment a patient is allocated 
to. In trials comparing vitamin K antagonists however, it is not possible without 
extended sham procedures to blind patients and physicians since the half life of the 
vitamin K antagonist is needed to determine the dosage optimally. We believe that 
at the level of the patient we did not introduce any bias as result of the non 
blindness of the trial. The outcome measure of this trial was the time spent in 
therapeutic range, i.e. the achieved INR. It is not likely that the patients’ 
knowledge about the vitamin K antagonist he or she is taking is of any influence on 
the measured INR. It could in theory affect a patients’ compliance to the treatment, 
but we do not have any reason to believe that the compliance will be different 
among the two groups. The knowledge of the physician to which treatment a 
patient is allocated to can be of influence on the time spent in therapeutic range. 
For example, a physician may be more cautious in one of the two treatment groups 
which would result in a shorter time between two INR measurements and less 
rigorous dosage changes. This would be evident in the data as a shorter time 
between two INR measurements in the group with the highest proportion of time 
spent in the therapeutic range. 
The patients included in our trial are all out-patients, and therefore 
represent a selection of all patients treated with vitamin K antagonists with a 
relatively high health status, since a relevant proportion of patients treated with 




vitamin K antagonists will be in-patients. Because this is a randomized trial this 
will not affect the validity of the results. In-patients are more likely to receive 
multiple and interacting medications and are more likely to have co morbidities. 
One may question therefore whether the results can be generalised to the total 
population of patients using vitamin K antagonists though there is no reason to 
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General Discussion & Summary 
 
Although the quality of oral anticoagulant treatment has improved over time, there 
still is considerable risk to experience a thrombotic and haemorrhagic 
complication. The risk for complications increases when patients are either under- 
or overanticoagulated. Improvement in dosing strategies is warranted. The studies 
included in this thesis aim to optimise dosing of vitamin K antagonists and control 
of oral anticoagulant treatment. 
 
Strategies for improvement of dosing of oral anticoagulants.  
In our double-blind controlled trial comparing a simple dosing algorithm to 
an algorithm which incorporated the patients’ sensitivity for vitamin K antagonists, 
we showed that there was no increase in quality of treatment, expressed as time 
spent within the therapeutic range (chapter 2). Also, the time between two visits 
was similar in both groups, although the interquartile range was broader for the 
new algorithm. However, the new algorithm was more efficient, as more dosage 
proposals were generated and accepted. For all visits combined, the standard 
algorithm generated an acceptable proposal in 55.3% of cases, which was 77.4% 
for the new algorithm. Finally, in almost all cases in which the standard algorithm 
did not result in a dosage proposal, a proposal was generated by the new algorithm. 
In these cases, the new algorithm performed as well as an unassisted physician. 
In chapter 3 we investigated the ‘transition factors’ between the 
maintenance dosages of three frequently used vitamin K antagonists for oral 
anticoagulant treatment. We observed that the maintenance dose of warfarin was 
0.41 (95%CI 0.39- 0.43) times the maintenance dose of phenprocoumon. The 
transition factor between acenocoumarol and phenprocoumon was 0.84 (95%CI 
0.79- 0.89) and between acenocoumarol and warfarin 1.85 (95%CI 1.78- 1.92). 
 




 In the prospective cohort study consisting of 220 Italian patients initiating 
oral anticoagulant treatment with acenocoumarol described in chapter 4, we 
showed that CYP2C9*3 was associated with a 25% dose reduction and an 
increased risk of over-anticoagulation (INR>6) on day 4. Two copies of the 
VKORC1*2 alleles were associated with a 45% dose reduction and an increased 
risk of over-anticoagulation. Both VKORC1*3 and VKORC1*4 homozygosity was 
associated with an increased dose requirement and a reduced risk of over-
anticoagulation. The VKORC1*3 or *4 + CYP2C9*1 genotype combination was 
associated with the highest dose requirement and the lowest INR on day 4; 
VKORC1*2 + CYP2C9*3 with the lowest dose requirement, the highest INR and 
an increased risk of over-anticoagulation. Even though they spent approximately 
50% of the time within the target therapeutic range, VKORC1*3 or *4 + 
CYP2C9*1 carriers spent a large percentage of the remaining time above and 
carriers of VKORC1*2 + CYP2C9*3 below the target range. 
 
Relevance of improved dosing strategies for clinical practice 
In recent years, interest in individualised dosing of pharmaceuticals based on a 
genetic profile has increased. For some drugs, genetic factors can be responsible 
for the majority of patient variability. Variability in response to vitamin K 
antagonists is in part mediated by genetic variability. In accordance with the results 
presented in chapter 4, several studies have reported variants in CYP2C9 and 
VKORC1 genes to be important for patients using warfarin or phenprocoumon, 
although there are some conflicting results [1-6]. Individualised dosing which 
incorporates the specific genotype of a particular patient could result in more 
appropriate dosages and less frequent over-anticoagulation in the initial phase of 
treatment. As we showed in chapter 4, patients who have a genotype which makes 
them more sensitive to vitamin K antagonists need lower maintenance dosages and 
 




are at increased risk for overanticoagulation in the initial phase of treatment. It is 
likely that reducing the starting dosages of these patients results in a reduction of 
overanticoagulation, and thus a decreased risk for bleeding complications. 
However, knowledge of the specific genotype of a patient in the maintenance phase 
of treatment is less likely to result in an improvement of therapy as reflected by the 
time spent within the therapeutic range. As demonstrated in chapter 2, dosing 
during the maintenance phase assisted by a computerised algorithm which 
incorporated the sensitivity of a patient for the anticoagulant did not result in an 
increased quality of treatment. The sensitivity factor used by the algorithm was 
based on the patients’ response to previous dosages. This response partly depends 
on the genotype of a particular patient, and therefore the effect of the genotype is 
already reflected in the calculated sensitivity factor.  
Using one single algorithm for generation of dosage proposals is most 
efficient for daily clinical practice. An algorithm which incorporates the genotype 
of the patient may be beneficial compared to an algorithm without this information, 
due to a possible advantage in the initial phase of treatment. But, the response to 
vitamin K antagonists is not entirely dependent from a patient’s genetic profile. 
Removing the variability due to the genetic profile still leaves a substantial 
variability in response to vitamin K antagonists and the effect on clinical endpoints 
may not outweight the costs for genetic testing. A prerequisite for genotype-based 
dosing is the availability of bedside genotype tests, since the genotype is already 
required for the first dosing proposal. To investigate the potential benefit of 
genotype-based dosing a randomised controlled trial should be performed.  
 
Using the calculated transition factors reported in chapter 3 physicians are able to 
estimate the new maintenance dosage in case a patient needs to switch from one 
vitamin K antagonist to another. However, two important limitations for the use of 
 




these transition factors require attention. First, the genotype may also influence 
these transition factors, as from other studies it is known that sensitivity for 
different vitamin K antagonists varies per genotype. In theory, in a patient who has 
a genotype which results in an extreme sensitivity for warfarin but not for 
phenprocoumon, switching may result in either under- or over-coagulation 
depending on the direction of the switch. In our study described in chapter 3, we 
could not investigate this since DNA  was not available. Second, we only 
determined the transition factor between maintenance dosages. Since switching 
from one vitamin K antagonist to another also requires a transition scheme, it 
remains unknown what dosages are needed in the initial days after switching for 
optimal safety. Only one other study investigated a dosage scheme for transition 
from phenprocoumon to warfarin in patients treated in an outpatient clinic [7]. 
Because of these two important limitations, patients who switch from one vitamin 
K antagonist to another require frequent monitoring during the initial phase after 
transition. 
Future studies that investigate switching between different types of vitamin 
K antagonists should address the potential influence of genotype on the transition 
factors, as well as the optimal dosing scheme for transition.  
 
Stability of oral anticoagulant treatment.  
Besides improving dosing of oral anticoagulants, monitoring of patients is also 
important. If one could identify patients at high risk for complications, precautions 
can be taken to avoid these complications. 
In a study of 630 subjects with mechanical heart valve prostheses we found 
that unstable anticoagulation was associated with an increased risk of haemorrhagic 
and thrombotic complications (chapter 5). Both variability and time spent outside 
the target range affected risk. The variance growth rate described by Fihn, method 
 




A, incorporates both aspects of instability, and was therefore most clearly 
associated with complications of anticoagulant therapy, especially haemorrhagic 
episodes. Thrombotic events were most clearly predicted with variability calculated 
with method B1 and B2, which only concerns variability of the INR and not the 
time within range. The optimal time window to determine these measures was 
three months. In chapter 6 we showed that unstable anticoagulation is observed 
more frequently with the use of acenocoumarol versus phenprocoumon, in 
individuals with daily strenuous physical activity, and less frequently in obese 
patients. Patients who are obese, have daily strenuous physical activity, or are 
frequent alcohol users have a higher risk of being more frequently out of range. 
Furthermore, increased anticoagulant dosage substantially reduced the risk of being 
frequently out of range.  
Finally, in chapter 7 we described the study design of our trial of which 
the primary aim is to compare the quality of a treatment with warfarin to the 
quality of a treatment with phenprocoumon. In addition we gave an overview of the 
overall quality of anticoagulant treatment, without giving the results for the two 
treatment groups separately since the trial is ongoing. The overall quality of 
anticoagulant treatment was high, with a median time spent within the therapeutic 
range of 74.7% (IQR 58.8-87.0). 
 
The quality of oral anticoagulant treatment depends on a combination of the 
percentage of time spent within the therapeutic range and instability of 
anticoagulation. Both factors have their own risk factors and may require their own 
management. 
The achieved intensity of anticoagulation was less important in predicting 
thrombotic events than haemorrhagic events. Variability, however, seems to be 
most predictive for thrombotic complications. This may be because time spent 
 




outside the therapeutic range for the greater part consists of overanticoagulation 
rather than underanticoagulation. Highly variable INRs result in a disturbed 
balance between procoagulant and anticoagulant factors which may lead to a 
procoagulant state, although there is no clear explanatory mechanism. Initiation of 
oral anticoagulant treatment is associated with a temporary hypercoagulable state 
due to the difference in half life between pro- and anticoagulant factors. Each time 
the INR rises again in a patient who is unstably anticoagulated, a hypercoagulable 
state may be temporary present as a result of a similar mechanism. 
Other studies have also shown that variability is a risk factor for 
complications of anticoagulant treatment [8-10]. For daily clinical practice this 
means that physicians should not interpret an INR within the therapeutic range for 
a patient with highly variable INRs the same as an INR within range of a patient 
whose INRs are always within range. 
 
Several studies have compared the quality of treatment with acenocoumarol to a 
treatment with warfarin or phenprocoumon. The results with respect to stability are 
mostly, but not always in favour of the longer acting vitamin K antagonists [11-
19]. In our study described in chapter 6 acenocoumarol was shown to be a risk 
factor for unstable anticoagulation, which is also in accordance with an earlier 
study investigating risk factors for unstable anticoagulation [20]. Acenocoumarol 
should therefore only be used in patients in whom short acting drugs are preferred, 
such as women trying to get pregnant. In all other patients a longer acting vitamin 
K antagonist should be used, either warfarin or phenprocoumon. Which one of 
these two vitamin K antagonists results in the highest quality of treatment can be 
answered with the results of the trial described in chapter 7. 
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Ondanks dat de kwaliteit van de antistollingsbehandeling met vitamine K 
antagonisten door de jaren heen is verbeterd, bestaat er nog steeds het risico op het 
krijgen van een trombotisch- dan wel bloedingscomplicatie. Het risico op een 
complicatie neemt toe wanneer patiënten te sterk, dan wel niet sterk genoeg 
ontstold zijn. Verbeteringen in doseerstrategieën zijn daarom  wenselijk. In dit 
proefschrift worden diverse onderzoeken beschreven die als doel hebben het 
doseren of controleren van de orale antistollingsbehandeling te optimaliseren. 
 
Strategieën voor het verbeteren van doseren van orale anticoagulantia 
In een dubbelblind gerandomiseerde gecontroleerde trial hebben we het doseren 
met behulp van een eenvoudig computer algoritme hebben vergeleken met doseren 
met behulp van een computer algoritme waarin de gevoeligheid van de patiënt voor 
vitamine K antagonisten geïncorporeerd was. In deze studie hebben we laten zien 
dat de kwaliteit van de behandeling niet toeneemt bij gebruik van het nieuwe 
algoritme, gemeten aan de hand van het percentage tijd dat in de therapeutische 
zone is doorgebracht (hoofdstuk 2). Ook de tijd tussen twee INR controles was 
gelijk in beide groepen, hoewel de interquartile range (IQR) wijder was bij het 
nieuwe algoritme. Aan de andere kant was het nieuwe algoritme wel efficiënter 
omdat deze meer doseervoorstellen genereerde en de voorstellen ook vaker door de 
arts geaccepteerd werden. Het standaard algoritme genereerde een acceptabel 
voorstel in 55.3% van de gevallen, tegen 77.4% door het nieuwe algoritme. Tot 
slot, in bijna alle gevallen waarbij het standaard algoritme niet in staat was een 
doseervoorstel te genereren, was dit wel het geval bij het nieuwe algoritme. In deze 
gevallen was het nieuwe algoritme net zo goed als een arts zonder de hulp van een 
computer algoritme. 




Soms moet een patient switchen van vitamine K antagonist vanwege een 
overgevoeligheidsreactie of een zwangerschapswens, waarbij een langwerkend 
middel niet geprefereerd wordt. In hoofdstuk 3 hebben we omrekeningsfactoren 
onderzocht tussen de onderhoudsdoseringen van de 3 meest gebruikte vitamine K 
antagonisten. We observeerden dat de onderhoudsdosering van warfarine 0.41 
(95%BI 0.39-0.43) keer de onderhoudsdosering van fenprocoumon was. De 
omrekeningsfactor tussen acenocoumarol en fenprocoumon was 0.84 (95%BI 0.79- 
0.89) en tussen acenocoumarol en warfarine 1.85 (95%BI 1.78- 1.92). 
 In een prospectief cohort onderzoek met 220 Italiaanse patiënten die 
startten met een orale antistollingsbehandeling met acenocoumarol beschreven in 
hoofdstuk 4, laten we zien dat CYP2C9*3 geassocieerd was met een 25% dosis 
reductie en een verhoogd risico op een doorgeschoten antistolling (INR>6) op dag 
4. Twee kopieën van de VKORC1*2 allelen waren geassocieerd met een 45% 
dosis reductie en een verhoogd risico een doorgeschoten antistolling. Zowel 
VKORC1*3 als VKORC1*4 homozygotie was geassocieerd met een verhoogde 
dosis behoefte en een verlaagd risico op doorgeschoten antistolling. Het 
VKORC1*3 of *4 en CYP2C9*1 genotype gecombineerd was geassocieerd met de 
hoogste dosis behoefte en de laagste INR op dag 4; VKORC1*2 en CYP2C9*3 
met de laagste dosis behoefte, de hoogste INR en een verhoogd risico op een 
doorgeschoten antistolling. Hoewel ze beiden ongeveer 50% van de tijd binnen de 
therapeutische zone zijn, zijn dragers van VKORC1*3 of *4 + CYP2C9*1  een 
hoger percentage van de overgebleven tijd  boven de therapeutische zone, terwijl 
dragers van VKORC1*2 + CYP2C9*3 een hoger percentage van de tijd beneden 
de therapeutische zone zijn. 
 




Relevantie van verbeterde doseerstrategieën voor de klinische praktijk 
In de afgelopen jaren is interesse in het doseren van medicijnen op individuele 
basis gebaseerd op het genetische profiel toegenomen. Voor sommige medicijnen 
kunnen genetische factoren voor een belangrijk deel verantwoordelijk zijn voor van 
de variabiliteit bij patiënten. Ook de variabiliteit in de respons op vitamine K 
antagonisten kan gedeeltelijk worden verklaard door genetische variabiliteit. In 
overeenstemming met de resultaten gepresenteerd in hoofdstuk 4 hebben 
verschillende andere studies gerapporteerd dat variaties van CYP2C9 en VKORC1 
belangrijk zijn voor patiënten die warfarine of fenprocoumon gebruiken, alhoewel 
dit niet in alle studies gevonden is. Een patiënt-specifiek doserings advies dat 
rekening houdt met het specifieke genotype van de patiënt leidt mogelijk tot betere 
doseeradviezen en minder frequent doorschieten van antistolling in de startfase van 
de behandeling. Zoals we hebben laten zien in hoofdstuk 4, hebben patiënten met 
een genotype dat hen gevoeliger maakt voor vitamine K antagonisten een lagere 
onderhoudsdosering en hebben zij een verhoogd risico op het doorschieten van de 
antistolling in de beginfase van behandeling. Het is waarschijnlijk dat het 
reduceren van de startdoseringen van deze patiënten resulteert in het minder 
frequent doorschieten van de antistolling, en dus mogelijk een verlaagd risico op 
bloedingscomplicaties. Echter, kennis van het specifieke genotype van de patiënt is 
waarschijnlijk minder van belang in de onderhoudsfase van de behandeling. Zoals 
beschreven in hoofdstuk 2 resulteerde het doseren met behulp van een computer 
algoritme waarin de gevoeligheid voor het antistollingsmiddel geïncorporeerd was 
niet tot een verhoogde kwaliteit van de behandeling in de onderhoudsfase. De 
gevoeligheidsfactor die gebruikt werd door het algoritme was gebaseerd op de 
respons van de patiënt op eerdere doses. Deze respons hangt gedeeltelijk af van het 
genotype van de specifieke patiënt waardoor het effect van het genotype al 
opgenomen is in de berekende gevoeligheidsfactor. 




Het gebruiken van één algoritme voor het generen van doseervoorstellen is 
het meest efficiënt voor de dagelijkse klinische praktijk. Een algoritme dat 
rekening houdt met het genotype van de specifieke patiënt is mogelijk geschikter 
dan een algoritme zonder deze informatie, door het mogelijke voordeel in de 
startfase van behandeling. Echter, de respons op vitamine K antagonisten is niet 
alleen maar afhankelijk van het genetisch profiel van de patiënt. Het verwijderen 
van de variabiliteit in de respons veroorzaakt door het genetisch profiel, laat nog 
een substantieel gedeelte van de variabiliteit in de respons op vitamine K 
antagonisten over en het effect op klinische eindpunten weegt mogelijk niet op 
tegen de kosten van het genotyperen. Een voorwaarde voor het genotype 
gemedieerde doseren is het beschikbaar zijn van sneltesten, aangezien het genotype 
al voorhanden moet zijn voor het eerste doseeradvies. Om dit mogelijke voordeel 
van genotype gemedieerd doseren te onderzoeken zou er een gerandomiseerde 
gecontroleerde trial uitgevoerd moeten worden.  
 
Met behulp van de berekende vermenigvuldigingsfactoren gerapporteerd in 
hoofdstuk 3 kunnen artsen de nieuwe onderhoudsdosering schatten wanneer een 
patiënt van één vitamine K antagonist naar een andere moet wisselen. Echter, er 
zijn twee belangrijke beperkingen voor gebruik van deze 
vermenigvuldigingsfactoren. Allereerst, het genotype van de patiënt kan van 
invloed zijn op de vermenigvuldigingsfactor, omdat uit andere onderzoeken bekend 
is dat de gevoeligheid voor verschillende vitamine K antagonisten per genotype 
verschilt. In theorie kan wisselen bij een patiënt met een genotype dat resulteert in 
een extreme gevoeligheid voor warfarine maar niet voor fenprocoumon, resulteren 
in een te lage dan wel een doorgeschoten antistolling, afhankelijk van de richting 
van het wisselen. In onze studie beschreven in hoofdstuk 3 konden we dit helaas 
niet onderzoeken omdat van deze patiënten geen DNA  beschikbaar was. Ten 




tweede hebben we alleen vermenigvuldigingsfactoren berekend voor de 
onderhoudsdosering. Aangezien voor het wisselen van de ene vitamine K 
antagonist naar de andere ook een overgangsschema nodig is, blijft onbekend 
welke doses in de eerste dagen na het wisselen nodig zijn voor een optimale 
veiligheid. Slechts één andere studie heeft een overgangsschema voor het wisselen 
van fenprocoumon naar warfarine onderzocht in poliklinische patiënten. Vanwege 
deze twee belangrijke beperkingen, zal in de eerste dagen na het wisselen toch 
frequente INR controle nodig zijn.  
Toekomstige studies die het wisselen tussen verschillende types vitamine 
K antagonisten onderzoeken moeten aandacht besteden aan de invloed van het 
genotype op de vermenigvuldigingsfactor, alsmede aan het optimale 
doseringsschema voor de periode vlak na het wisselen.  
 
Stabiliteit van orale antistollingsbehandeling.   
Naast het verbeteren van het doseren van antistollingsmiddelen, is het monitoren 
van patiënten ook belangrijk. Wanneer men in staat is patiënten te identificeren die 
een verhoogd risico hebben op complicaties, kunnen er voorzorgsmaatregelen 
worden getroffen teneinde deze complicaties te voorkomen. 
In een onderzoek met 630 deelnemers met mechanische hartklep prothesen 
vonden we dat instabiele antistolling geassocieerd was met een verhoogd risico op 
bloedings- en trombotische complicaties (hoofdstuk 5). Zowel instabiliteit als de 
tijd buiten de therapeutische zone hadden invloed op dit risico. Er bestaan diverse 
methoden om instabiliteit weer te geven. De variance growth rate beschreven door 
Fihn, methode A, houdt rekening met beide aspecten van instabiliteit, en was 
waarschijnlijk daardoor het meest geassocieerd met complicaties van 
antistollingsbehandeling, vooral bloedingcomplicaties. Trombotische complicaties 
werden het best voorspeld met de variabiliteit berekend met methode B1 en B2, 




een methode die alleen de variabiliteit weergeeft van de INR en niet de tijd 
doorgebracht in de therapeutische zone. Het optimale tijdwindow om deze maten te 
berekenen was 3 maanden. In hoofdstuk 6 hebben we laten zien dat instabiele 
antistolling vaker gezien wordt bij patiënten die acenocoumarol gebruiken ten 
opzichte van fenprocoumon gebruikers, bij patiënten die dagelijks zware 
lichamelijke activiteit hadden en minder vaak in obese patiënten. Patiënten met 
obesitas, dagelijkse zware lichamelijke activiteit of patiënten die frequent alcohol 
gebruiken hadden een verhoogd risico meer tijd buiten de therapeutische zone door 
te brengen. Verder hadden patiënten met een hoge dosis van hun 
antistollingsmiddel een substantieel lager risico om vaak buiten de therapeutische 
zone te zijn.  
Tenslotte beschrijven we in hoofdstuk 7 het studie design van onze trial 
waarin het hoofddoel is de kwaliteit te vergelijken van een antistollingsbehandeling 
met warfarine ten opzichte van fenprocoumon. Tevens geven we hier een overzicht 
van overall kwaliteit van de antistollingsbehandeling, zonder de resultaten van 
beide groepen weer te geven omdat de trial nog niet beëindigd is. De kwaliteit was 
hoog, met een mediane tijd doorgebracht in de therapeutisch zone van 74.7% (IQR 
58.8-87.0). 
 
De kwaliteit van een orale antistollingsbehandeling hangt af van een combinatie 
van het percentage tijd doorgebracht in de therapeutische zone en de instabiliteit 
van de antistolling. Beide aspecten van de kwaliteit van de behandeling hebben hun 
eigen risicofactoren en beide aspecten hebben wellicht een geïndividualiseerde 
aanpak nodig.  
De bereikte intensiteit van de antistolling was minder belangrijk in het 
voorspellen van trombotische complicaties dan van bloedingscomplicaties. De 
variabiliteit lijkt echter het meest voorspellend te zijn voor trombotische 




complicaties. Dit kan veroorzaakt worden omdat de tijd doorgebracht buiten de 
therapeutische zone voor het grootste gedeelte bestaat uit doorgeschoten 
antistolling in plaats van antistolling beneden de therapeutische zone. Hoge 
variabele INRen resulteren in een verstoorde balans van procoagulante en 
anticoagulante factoren en dit kan leiden tot een tijdelijke procoagulante status, 
alhoewel daar nog geen duidelijk verklarend mechanisme voor is. Het starten met 
een orale antistollingsbehandeling is geassocieerd met een tijdelijke 
hypercoagulabele status, vanwege de verschillen in halfwaarde tijd van de pro- en 
anticoagulante factoren. Iedere keer wanneer de INR stijgt in een instabiel 
ontstolde patiënt kan deze hypercoagulabele staat aanwezig zijn als gevolg van 
eenzelfde mechanisme. 
Andere studies hebben ook laten zien dat variabiliteit een risico factor is 
voor complicaties van orale antistollingsmedicijnen. Voor de dagelijkse klinische 
praktijk betekent dit dat artsen een INR binnen de therapeutische zone van een 
patiënt met zeer variabele INRen niet hetzelfde moeten interpreteren dan een INR 
in de therapeutische zone van een patiënt waarvan de INR altijd binnen de zone 
zijn. 
 
Verschillende onderzoeken hebben de kwaliteit van een antistollingbehandeling 
met acenocoumarol vergeleken met een behandeling met warfarine of 
fenprocouomon. De resultaten zijn meestal, maar niet altijd in het voordeel van de 
langer werkende vitamine K antagonisten. In onze studie beschreven in hoofdstuk 
6 was het gebruik van acenocoumarol een risico factor voor instabiele antistolling, 
wat overeen komt met de resultaten van een eerdere studie die risico factoren voor 
instabiele antistolling onderzocht heeft. Acenocoumarol zou daarom alleen 
gebruikt moeten worden in patiënten bij wie kortwerkende medicijnen de voorkeur 
verdienen, zoals vrouwen met een zwangerschapswens. Bij alle andere patiënten 




heeft een langer werkende vitamine K antagonist de voorkeur, zowel warfarine of 
fenprocoumon. Welke van deze 2 vitamine K antagonisten resulteert in de hoogste 
kwaliteit van de behandeling kan beantwoord worden met de resultaten van de trial 















Natuurlijk was dit proefschrift er niet gekomen zonder de hulp en steun van vele 
mensen. Ik wil iedereen die mij geholpen heeft dan ook bedanken voor hun 
bijdrage. 
 
Graag wil ik de medewerkers van de Trombosedienst Leiden bedanken voor het 
vele werk dat zij belangeloos voor mij en de warfarine trial verricht hebben. Het 
viel niet mee om alle warfarine tabletten op de juiste plek te krijgen, zonder jullie 
was dat nooit gelukt. En dan had ik er ook nog eens een neus voor om te komen 
opdagen als er bij jullie weer eens op lekkers getrakteerd werd. 
De afdelingen Cardiologie en Interne Geneeskunde van het Diaconessenhuis 
Leiden (dr. A.A. de Rotte, dr. E.V. Planken), Rijnland Ziekenhuis Leiderdorp (dr. 
C.J.H.J. Kirchhof, dr. F.H.M. Cluitmans), LUMC (dr. H.F. Verwey, dr. E.A. 
Compier) en de afdeling orthopedie van het LUMC (dr. H.M.J. van der Linden- 
van der Zwaag, Mery) bedankt voor jullie medewerking aan de warfarine trial. Ook 
alle medewerkers van de trombosedienst Den Haag, in het bijzonder Carin en 
Milia, bedankt voor alles wat jullie gedaan hebben voor mij. 
Marta, it was a pleasure to work with you during your stay here in Holland. Can 
you still sing the song ‘Tulpen uit Amsterdam’? 
Renée, Ingeborg, Lucie, Yael, Marieke, Edward, ik ben jullie ontzettend dankbaar 
dat ik jullie te pas en te onpas de pieper mocht toevertrouwen. Edward, fijn dat jij 
de laatste loodjes van de warfarine trial op je wilde nemen. Het is klaar! 
Alle collega’s wil ik bedanken voor de leuke tijd die ik gehad heb. In het bijzonder 
Yvonne, bedankt voor al je hulp en gezelligheid en wat fijn dat je voor mij het 
gevecht met de lay-out van dit boekje aan wilde gaan! En natuurlijk C9-36: 




Martijn, Nora, Karlijn, Mirjam, Jaap-Jan en Alette, bedankt voor jullie gezellige 
aanwezigheid, de taart en koekjes, de vele kopjes thee en capu’s. Maar uiteraard 
ook voor de wetenschappelijke discussies, nieuwe feitjes over dierengedrag en de 
Engelse uitspraak oefensessies met James. 
Eva, Anja en Sas, begonnen als Factor IV Leiden op Sicilië hebben we ontzettend 
veel lol gehad. En nog steeds ben ik heel blij dat ik jullie tegengekomen ben. Eef 
en Sas, leuk dat jullie tijdens de verdediging naast me staan! 
Mutsen, bedankt voor jullie begrip en interesse. Mir, John, fijn dat ik bij jullie tot 
rust mocht komen in roerige tijden. Mies, bedankt voor je geduld bij het eindeloos 
verzetten van sportafspraken en je tijd die je besteed hebt aan het lezen en aanhoren 
van het wel en wee van mijn werkzaamheden. Nicolette, ondanks dat er weinig tijd 
was van beide kanten, vonden we toch altijd een gaatje om af te spreken. Bedankt 
voor deze ontspannende momenten. Mijn drukke werkzaamheden zijn nu voorbij, 
nu de jouwe nog! 
 
Patries, bedankt voor de prachtige omslag. 
 
Mijn ouders: bedankt  voor jullie onvoorwaardelijke liefde en steun, en stimulatie 
om vooral door te gaan. Martin, je bent de beste broer die ik me kan wensen! 
 
Lieve Ton, jij bent het allermooiste dat ik aan het schrijven van dit proefschrift heb 
overgehouden. Met jou is elke dag een feestje en de gedachte dat er nog vele 
feestjes zullen volgen maakt mij intens gelukkig. Ik kijk uit naar onze grote dag 
over een paar maanden! 
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